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Thesis Abstract 
Thesis Abstract 
Hypertension is a chronic, complex pathophysiological state that leads to 
serious complications such as cardiovascular disorders, stroke and abnormal renal 
function. Epidemiological studies have shown that the plienotypic variation in blood 
pressure is genetically and environmentally determined. 
Left ventricle hypertrophy compensates pressure overload during 
hypertension and normalizes systolic wall stress, thus cardiac function is maintained. 
Cardiac hypertrophy, however, is accompanied by myocardial remodeling, including 
alteration in gene expression, death of cardiomyocytes, insufficient vascularization 
and fibrosis. These responses are followed by a transition to heart failure. The 
pathogenesis of hypertension-induced diseases is still not fully understood. 
In this research project, the differential gene expression in the heart of 
Spontaneously Hypertensive Rat was studied while Wistar Kyoto rat was employed 
as the normotensive control. Combining suppression subtractive hybridization and 
microarray techniques, differentially expressed genes were screened out which were 
further confirmed by reverse-transcription polymerase chain reactions and Northern 
blot hybridizations. These genes are potentially involved in the pathogenesis of 
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Introduction 
Chapter 1: Introduction 
1.1 Research Initiative and Significance 
Cardiovascular disease (CVD) is a leading cause of mortality and is 
responsible for one-third of all global deaths (Figure 1). CVD is one of the most 
important causes of mortality and morbidity in the elderly population (World Health 
Organization, 2001). In China, approximately 65% of CVD deaths are in people 
older than 70 years old (World Health Organization, 2002). In Hong Kong, CVD is 
the second leading cause of death, in which most of the cases of CVD are directly or 
indirectly related to hypertension (Department of Health, HKSAR, 2003). 
Hypertension is a complex pathophysiological state that leads to serious 
complications in the cardiovascular system, such as coronary artery disease, ventricle 
hypertrophy, cardiac arrhythmia，cardiomyopathy and heart failure (Munroe PB and 
Caulfield MJ, 2000; Sellers KW et al, 2001). Among all cases of hypertension, more 
than 90% has unknown cause, which is classified as essential or primary 
hypertension. In general, hypertension prevalence is higher in urban settings 
compared to rural settings. In developed and developing countries, essential 
hypertension affects 25% to 35% of the adult population, and up to 60% to 70% of 
elderly above 70 years old (Staessen JA et al, 2003). 
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The genetic basis of essential hypertension is complex and the pathological 
mechanism still remains largely unknown (Williams SM et al, 2000). In order to 
understand the pathological consequence of hypertension to hypertrophy and 
eventually heart failure, the differential gene expression pattern of hypertensive heart 
is studied. By combining suppression subtractive hybridization and cDNA 
microarray techniques, candidate genes are identified for the further analysis. These 
genes may play crucial roles in the pathological mechanism of the hypertension-
induced hypertrophy and heart failure. 
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Figure 1 Leading causes of death for Asian/Pacific Island populations. 
Statistic shows the leading cause of death for Asian and Pacific Island populations 
adapted from America Heart Association, 2000. The diseases of heart and stroke are 
the leading cause of death in Asian and Pacific Island populations both in males and 
females. 
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1.2 Cardiomyocyte and Terminal differentiation 
Cardiomyocyte is the most physically energetic cell in the body and contract 
constantly 3 billion times or more in an average human lifespan. Coordinating with 
the heartbeat activity, over 7,000 litres of blood are pumped per day, without 
conscious effort, along 100,000 miles of blood vessels (Severs NJ, 2000). 
Terminal differentiation is the process during which specified cells express 
cell-specific proteins that confer their phenotypic identity (Lough J and Sugi Y, 2000). 
Cardiomyocytes are derived from the mesodermal germ layer and proliferate rapidly 
during embryogenesis (Solloway MJ and Harvey RP, 2003). Cardiomyocytes 
undergo terminal differentiation soon after birth and are generally considered to 
irreversibly withdraw from the cell cycle (Soonpaa MK and Field LJ, 1998; 
Tamamori M et al, 1998). At the same time, protein synthesis, which is rapid in the 
proliferating embryonic heart, slows to the rates appropriate for cell maintenance and 
repair (Katz AM, 1994). During postnatal cardiac development, cardiomyocytes 
undergo a rapid switch in the transition from hyperplastic and hypertrophic growth 
between days 3 and 4 in rat heart (Figure 2). Cell number increases from the 
postnatal day 1 to 3 and remained constant thereafter. Since the increase in cell 
volume and binucleation of cardiomyocytes begin at day 4, binucleation is an early 
- 4 -
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morphological indicator of cardiomyocyte that responds to the increasing mechanical 
load of the neonatal heart development (Li F et al, 1996; Chim SS et al, 2000). In 
humans, the capability to undergo mitosis and hyperplasia is lost 3 to 6 months 
postnatally (Limas CJ, 1987). The molecular pathways that lead to specification and 
terminal differentiation of cardiomyocytes from embryonic mesoderm during 
development are not entirely clear (Mummery C et al, 2002). 
However, the debate about the terminal differentiation of cardiomyocyte soon 
after birth in mammalian heart still continues (Anversa P and Kajstura J, 1997). 
Some studies have demonstrated that cardiomyocytes maintain a low but measurable 
level of DNA replication in the normal adult heart of human (Quaini F et al, 1994) 
and rats (Dowell RT and McManus RE III，1978; Cheng W et al, 1995). Others have 
also suggested the existence of a limited degree of hyperplastic growth in either the 
normal or diseased myocardium (Soonpaa MH and Field LJ，1998). 
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Figure 2 Terminal differentiation of cardiomyocyte. 
This figure shows terminal differentiation of cardiomyocytes. Growth factors 
stimulate protein synthesis for cell division and proliferation in the embryonic heart. 
Cardiomyocytes are increased both in cell number and size. In adult heart, 
cardiomyocytes are terminally differentiated. Cell division is blocked at the G � p h a s e 
of cell cycle and protein synthesis is reduced to the level for cell maintenance and 
repair. 
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1.3 Hypertension and Myocardial Hypertrophy 
1.3.1 Hypertension 
Hypertension, or elevated arterial blood pressure, is a chronic, complex 
pathophysiological state that is the major risk factor for many common causes of 
morbidity and mortality including stroke, most of the cardiovascular diseases and 
end-stage renal disease (Berkin KE and Ball SG, 2001; Lifton RP et al, 2001). It is 
defined as a persistent high blood pressure that a level of systolic blood pressure of 
HOmmHg or above, or a level of diastolic blood pressure of 90mmHg or above. 
(World Health Organization, 1987). About 25% to 35% of the adult population 
worldwide is afflicted with hypertension. In those older than 60 years of age, as 
many as one-half are hypertensive in some populations. In general, hypertension 
prevalence is higher in urban settings compared to rural settings. Furthermore, 
because of the asymptomatic nature, hypertension is so-called a "silent killer" and 
the patients are often unaware of the disease until serious complications are caused 
(World Health Organization, 2002). 
Hypertension is a multi-factorial disease that is suggested to be determined by 
genetic, environmental and structural factors. Genetic contribution of blood pressure 
variation ranges from 30 to 50% (Ward R，1990; Kotchen TA et al, 2000). 
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Hypertension is a polygenic disease that means a number of genes with smaller 
effects，rather than a single hypertension gene, accounts for the heritability of this 
complex disorder (Timberlake DS et al, 2001). Environmental factors include 
psychosocial excitatory influences, high salt intake, obesity, alcoholism and lack of 
exercise. The structural factors, which dominate early cardiovascular function and 
pressure control, are genetically reinforced, therefore contributing to polygenic 
predisposition (FolkowB, 1993). 
1.3.2 Myocardial Hypertrophy 
Myocardial hypertrophy, especially left ventricular hypertrophy, is an early 
sign during the clinical course of heart failure. In general, cardiomyocytes in adult 
hearts are terminally differentiated and, therefore, cannot re-enter the cell cycle. 
Moreover, myocardium lacks a stem cell population for generation of new 
cardiomyocytes (Hunter JJ and Chien KP, 1999). During hypertension, abnormal 
growth factors are released. Cardiomyocytes grow in cell size without cell division to 
adapt a demand for an increased workload and this leads to compensatory left 
ventricular hypertrophy (Figure 3). 
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The pathological time course of hypertensive heart disease includes 2 stages. 
Initially, myocardial hypertrophy of the left ventricle compensates pressure overload 
and normalizes systolic wall stress, thus cardiac function is maintained. Although 
myocardial hypertrophy is compensatory for an increased workload, this adaptive 
response is accompanied by structural modifications of cardiac muscle, including 
alteration in gene expression, loss of cardiomyocytes, defective vascular 
development and fibrosis (Fortune MA et al, 2001; Komuro I, 2001). Prolonged 
hypertrophy leads to congestive heart failure, progressive contractile dysfunction, 
arrhythmia and sudden death (Lorell BH and Carabello BA, 2000). At the cellular 
level, cardiac hypertrophy is characterized by an increase in cell size, protein 
synthesis, assembly of sarcomeres and activation of fetal gene expression 
(Sadoshima J and Izumo S, 1997; Liu ZP and Olson EN, 2002; Akazawa H and 
Komuro I, 2003). In the presence of growth stimuli, the morphological expression of 
cardiac tissue remodeling develops to concentric compensatory hypertrophy or 
eccentric hypertrophy, followed by chamber dilation, to restore the left ventricle wall 
stresses (Chien KR, 1999; Zhang J, 2002). Apoptosis of cardiomyocytes is then 
induced (Figure 4). Cardiomyocyte apoptosis has been demonstrated during the 
transition from compensatory hypertrophy to heart failure (Li Z et al, 1997; 
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Anversa P, 2000; Kang PM and Izumo S, 2000). However, the mechanism and role 
of apoptosis in heart failure are still not fully understood (Schaper J et al, 1999). 
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Figure 3 The development of hypertensive hypertrophy. 
This figure shows the development of hypertensive hypertrophy. Pressure overload 
triggers the release or unnatural growth factors causing abnormal growth and 
ventricle hypertrophy, which is shown with red solid lines. Pressure overload also 
induces mechanical stress for abnormal growth and ventricle hypertrophy, which is 
shown with red broken line. 
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Figure 4 Morphology of ventricular cell in myocardial hypertrophy. 
This figure shows the morphological changes of ventricular cell in myocardial 
hypertrophy. Growth stimuli released during hypertension trigger the morphological 
changes in heart and cause apoptosis. 
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1.4 Experimental Animal Models 
In cardiovascular research, animal models have always been used to study 
chronic heart disease in the early stages as well as to investigate the mechanisms of 
the pathogenesis and the effects of drug intervention (Table 1). In general, an ideal 
animal model for any cardiovascular disease should meet various requirements; (i) 
the imitation of the animal model to human heart failure should be as close as 
possible, (ii) the cause of heart failure should resemble that of the human heart, (iii) 
the model should allow studies of a chronic stable state of heart failure, (iv) the 
model should produce symptoms which are predictable and controllable, (v) the 
model should allow measurement of relevant cardiovascular biochemical and 
haemodynamic parameters, and (vi) the model should satisfy economical, technical 
and animal welfare considerations (Doggrell SA and Brown L, 1998; Muders F and 
Eisner D, 2000). The most commonly used animal model of cardiovascular disease is 
the Spontaneously Hypertensive Rat (SHR) with Wistar Kyoto rat (WKY) as the 
normotensive control. 
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Table 1 Rat models of hypertension, cardiac hypertrophy and heart failure. 
Aetiology Models or Techniques References 
Systemic Hypertension Spontaneous Hypertensive Rat (SHR) Doggrell SA and Brown L, 1998 
Stroke-prone SHR (SHR-SP) Kim S et al, 1996 
Haas GJ et al, 1995 
Hypertensive HF prone rat (SHHF/Mcc-facp) 
Park Set al, 1997 
Dahl salt-sensitive rat Inoko M et al, 1995 
Morii le t al, 1998 
Pulmonary Hypertension Hypoxia Rabinovitch M et al, 1979 
Monocrotaline Ceconi C et al, 1989 
Hypertrophy Spontaneous Hypertensive Rat (SHR) Doggrell SA and Brown L, 1998 
Feldman AM et al, 1993 
Aortic banding 
Schunkert H et al, 1995 
Myocardial Infarction Coronary Ligation Pfeffer MA et al, 1979 
Medvedev OS and Gorodetskaya 
Microembolism 
EA, 1993 
Myocarditis Autoimmune IzumiTet al, 1991 
Chagas，disease Junqueira Junior LF et al, 1992 
Cardiomyopathy Adriamycin Wakasugi S et al, 1993 
Ethanol Capasso JM et al, 1992 
Catecholamine Grimm D et al, 1998 
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1.4.1 Spontaneously Hypertensive Rats 
Spontaneously Hypertensive Rats (SHRs) are the descendants of an out-bred 
Wistar male with spontaneous hypertension from a colony in Kyoto, Japan, mating 
with a female with an elevated blood pressure, and then brother x sister mating 
continued with selection for spontaneous hypertension, defined as a systolic blood 
pressure of over 150mm Hg persisting for more than one month. The inbred strain 
was further developed at the National Institutes of Health (NIH) in 1969 (Kurtz TW 
and Morris RC, 1987; Dzau VJ et al, 1995). 
SHRs are chronic stable animal models producing symptoms that are 
predictable and controllable without surgery and drug interventions. They follow the 
same progression of hypertension as human including pre-hypeitensive phase for the 
first 6 to 8 weeks of their lives with systolic blood pressure around 100 to 120 mmHg 
(Adams MA et al, 1989), developing phase and then hypertensive phase over the 
next 12 to 14 weeks (McGuire PG and Tweitmeyer TA, 1985; Folkow B, 1993). 
SHRs preserve normal cardiac function at the first year but progresses to heart failure 
during the last six months of their lifespan of about 2 years (Bing OH et al, 1995; 
Mitchell GF et al, 1997). Since hypertrophy in human is usually associated with 
chronic hypertension and SHRs have various stages of hypertension, they are 
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realistic animal models to be used in the study of development of hypertension, 
cardiac hypertrophy and eventually heart failure. As in human, hypertension 
develops more rapidly and becomes more severe in male SHR than female (lams SG 
and Wexler BC, 1979). The male SHR is commonly used as a model to define 
hypertension-induced changes in signaling mechanisms (Takata Y and Kato H, 1996; 
Boknik P et al, 2001). 
1.4.2 Wistar-Kyoto Rats 
The Wistar-Kyoto (WKY) rat controls were established in 1971 as a 
normotensive control strain by NIH. WKY was obtained from the colony in Kyoto 
from which the SHR strain was originally derived (Kurtz TW and Morris RC, 1987). 
They are commonly used as the normotensive controls for SHR rats in the studies of 
the cause, pathological mechanisms and the drug treatment of hypertension, 
hypertrophy and heart failure. 
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1.5 Combination of Suppression Subtractive Hybridization 
and cDNA Microarray Analysis 
1.5.1 Suppression Subtractive Hybridization 
The pathological mechanism of the transition from hypertension to 
myocardial hypertrophy is still not fully understood. However, the pathological 
pathway is suggested to be mediated by programs of differential gene expression. In 
order to understand the molecular regulation and find to candidate genes of this 
biological process, the relevant subsets of differentially expressed genes during 
hypertension must be identified, cloned and studied in detail. 
Subtractive cDNA hybridization is a powerful approach that allows the 
comparison of two populations of mRNA, identification and isolation of cDNAs of 
differentially expressed genes. Previously, numerous cDNA hybridization methods 
have been reported (Duguin JR and Dinauer MC, 1990; Hara E et cd, 1993). In 
general, the basic principle involves hybridization of tester cDNA, which contains 
the differentially expressed transcripts, to excess driver cDNA, which serves as a 
reference for comparison. The unhybridized cDNAs of differentially expressed 
cDNA are then separated from the hybridized common sequences. The separation 
process is usually accomplished by hydroxylapatite chromatography (Hedrick SM et 
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al’ 1984)，avidin-biotin binding (Sargent TD and Dawid IB, 1983), or oligo-dT latex 
beads (Hara E et al, 1991). However, these methods are tedious and labor intensive, 
which usually require greater than 20 fig of mRNA. 
Suppression subtractive hybridization (SSH), also known as PCR-based 
cDNA hybridization method, is then applied to study the molecular principle of the 
transition from hypertension to hypertrophy and heart failure. SSH selectively 
amplifies cDNA transcripts of differentially expressed genes and simultaneously 
suppresses DNA amplification of common sequences (Diatchenko L et al, 1996; 
Diatchenko L et al, 1999). SSH is based on the suppressive PCR effect. Suppression 
occurs when complementary sequences are present on each end of a single-stranded 
cDNA, followed by a formation of pan-like secondary structure (Siebert PD et al, 
1995). SSH overcomes the problem of differences in mRNA abundance by 
introducing a hybridization step for normalization of sequence abundance, due to 
standard hybridization kinetics, during the subtraction SSH eliminates any physical 
separation steps. It involves 2 rounds of hybridization and 2 rounds of PCR 
amplification. During the hybridization steps, the common cDNA sequences within 2 
populations hybridize together and the differentially expressed cDNA transcripts are 
enriched. The primary PCR amplification then selectively amplifies the differentially 
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expressed sequences. The secondary PGR amplification is performed to reduce the 
background PGR products and further enrich for the differentially expressed 
sequences (Figure 5). 
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Figure 5 Schematic diagram of suppression subtractive hybridization. 
This figure shows the principle of suppression subtractive hybridization that includes 
ligation of adaptors, 2 rounds of hybridization and PCR amplification. 
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1.5.2 cDNA Microarray Analysis 
cDNA microarray analysis is a high throughput method, which allows 
monitoring the gene expression patterns of hundreds to thousands of genes in parallel, 
and the most widely used functional genomics technique. Microarray is based on the 
hybridization of nucleic acid to a high-density matrix of immobilized target 
sequences (Duggan DJ et al, 1999). It provides high sensitivity and specificity of 
detection as a consequence of mutual selectivity between complementary strands of 
nucleic acids. 
The process of cDNA microarray analysis can be broadly divided into 3 
stages: array fabrication; probe preparation and hybridization; and data collection, 
normalization and analysis (Hegde P et al, 2000). It is constructed by arraying PCR-
amplified cDNA clones from the subtracted libraries at a high density on glass slides. 
Glass slides have several advantages over porous membranes and gel pads. Firstly, 
DNA samples can be covalently attached onto the treated glass surface. Secondly, 
glass is a durable material that sustains high temperature and washing steps of high 
ionic strength. Thirdly, it is non-porous so the hybridization volumes can be kept to 
minimum, thus enhancing the kinetics of annealing probes to targets. Fourthly, as a 
consequence of its low fluorescence, it does not significantly contribute to 
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background signal. Finally, 2 different probes can be labeled with different 
fluorescent dyes, and simultaneously incubated with a microarray in a single reaction 
while nylon arrays are restricted to serial or parallel hybridization (Cheung VG et al, 
1999; Southern E et al, 1999). The probes are then synthesized from SHR and WKY 
rat ventricles, in which RNAs are reverse-transcribed into cDNAs with incorporation 
of Cy3- or Cy5-labeled nucleotides. Two labeled probes are then co-hybridized to the 
microarray. Differential gene expression is studied with a single hybridization step 
that minimized the experimental variation in the comparison of independent 
hybridizations. The kinetics of hybridization allows relative expression levels to be 
determined based on the ratio with which each probe hybridizes to an individual 
array element (Schena M et cd’ 1995; Smith L and Greenfield A, 2003). Differential 
gene expression is assessed by the scanning of hybridized arrays with a confocal 
laser scanner that is capable to differentiate both Cy3- and Cy5- labeled probes and 
generate scanning images for data analysis. 
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Figure 6 The experimental flow of cDNA microarray analysis. 
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1.5.3 Combination of SSH and cDNA microarray 
Most Recently, combination of SSH and cDNA microarray have been 
employed for gene expression analysis (Aim JH et al, 2002; Rho J et al, 2002). One 
advantage of this approach is that differentially expressed genes can be screened out 
without identification of previously subtracted genes, which increase the flexibility 
of cDNA microarray to the study of differentially expressed novel genes. Moreover, 
SSH allows selective amplification of target cDNAs and simultaneously suppresses 
that of common sequences. Rare transcripts are also enriched during hybridization 
and PCR amplification steps. As a result, SSH increases the number of differentially 
expressed genes, and reduces the examination of multiple housekeeping genes. In 
addition, cDNA microarray technique allows the high throughput screening of 
subtracted clones. Numerous potential candidate genes are therefore fished out in 
parallel for the further analysis (Porkka K and Visakopi T, 1999; Yang GP et al, 
1999; Jiang Y, 2002). 
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Chapter 2: Materials and Methods 
2.1 Experimental Animal Models 
Five individuals of 22 to 24 week-old Spontaneously Hypertensive Rats 
(SHR) and Wister-Kyoto (WKY) rats were used for the construction of subtractive 
libraries. During 22 to 24 week-old, SHR enters the hypertensive stage with 
persistent high blood pressure (Doggrell SA and Brown L, 1998). The precise stage 
of cardiac hypertrophy has not been defined well. Cardiac hypertrophy, however, is 
generally induced by hypertension thus it is suggested to develop later than the 
hypertensive stage. Those genes showing differential expression in the hypertensive 
period is mostly hypertension-related and potentially involve in the induction of 
hypertrophy. Heart tissues were harvested from SHR and WKY rats respectively and 
rinsed with diethyl pyrocarbonate (DEPC)-treated phosphate buffered saline (PBS). 
The ventricles were obtained and chopped into small pieces. The chopped ventricular 
tissue was flash-frozen and stored in liquid nitrogen to avoid RNA degradation. 
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2.2 RNA Isolation from Rat Ventricle 
2.2.1 Total RNA Isolation 
Ventricular tissues of 5 individuals of SHR and WKY rats were pooled 
respectively. Total RNAs were isolated from the pooled ventricular tissues of SHR 
and WKY rats. TRIZOL® Reagent (Invitrogen™ Life Technologies, Carlsbad, CA), 
a mono-phasic solution of phenol and guanidine isothiocyanate, was employed for 
the single step total RNA isolation from chopped ventricular tissue (Chomczynski P 
and Sacchi N, 1987). One hundred and fifteen milligrams of pooled ventricular tissue 
was homogenized in 1.5 ml of TRIZOL® Reagent until no visible tissue fragments 
remained. The homogenate was incubated at room temperature for 5 minutes. To 
remove insoluble materials from the homogenate, the homogenate was centrifuged at 
12,000 X g for 15 minutes at 4°C . The resulting pellet contained extracellular 
membranes, polysaccharides and high molecular weight DNA, while the supernatant 
contains RNA. The supernatant was collected and 0.3ml of chloroform was added for 
phase separation. The mixture was shaked vigorously for 15 seconds and incubated 
at room temperature for 2 minutes. The mixture was then centrifuged at 12,000 x g 
for 15 minutes at 4°C. The colorless upper aqueous phase was collected and 0.75 ml 
of isopropanol was added for RNA precipitation. The mixture was incubated at room 
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temperature for 10 minutes and centrifuged at 12,000 x g for 10 minutes at 4°C. The 
supernatant was discarded. The RNA pellet was washed with 1.5 ml of 75% ethanol, 
centrifuged at 7,500 x g for 5 minutes at 4°C and air-dried briefly. The dried RNA 
pellet was dissolved in 40^1 DEPC-treated sterile distilled water. Two microliters of 
RNA sample was mixed with 2 \x\ of 2X RNA loading buffer (60% formamide, 
7% formaldehyde, 1.25X MOPS, 12.5 mM EDTA，0.03% bromophenol blue, 0.03% 
xylene cyanol FF，150 \xg ethidium bromide), denatured at 65°C for 5 minutes and 
chilled on ice for 1 minute. The RNA sample was then analyzed on a 1.0% TAE 
agarose gel and visualized by UVIPhoto gel documentation system (UVITec, 
Cambridge, UK). The yield of RNA was also determined by UV spectrophotometry 
at wavelengths of 260nm and 280nm. The RNA sample was stored at -70°C. 
2.2.2 Deoxyribonuclease I Digestion 
Total RNA was subjected to Deoxyribonuclease I (DNase I), Amplification 
Grade (Invitrogen^'^ Life Technologies, Carlsbad, CA). DNase I digestion was 
performed with 2 |ig of RNA sample, IX DNase I reaction buffer (20 mM Tris-HCl 
[pH 8.4], 2 mM MgCb, 50 mM KCl), 2 Units DNase I (Amp Grade), and DEPC-
treated water. The reaction mixture was incubated at room temperature for 
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15 minutes. DNase I was inactivated by adding 2.5 mM EDTA solution with heating 
at 65°C for 10 minutes. The DNase I-digested RNA sample was analyzed on a 1.0% 
TAE agarose gel and stored at -70°C. 
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2.3 Suppression Subtractive Hybridization 
2.3.1 First-Strand cDNA Synthesis 
SMART™ PCR cDNA Synthesis Kit (BD Bioscience Clontech, Palo Alto, 
CA) was used for cDNA synthesis (Chenchik A et al, 1998). Two micrograms of 
each SHR and WKY DNase I-digested RNAs as well as the control human skeletal 
muscle mRNA was added to 2 |iM 3' SMART CDS Primer II A (5'- AAG CAG 
TGG TAT CAA CGC AGA GTA CT(3o)N-i N -3'), where N = A, C, G，or T and N.i 
= A , G, or C, 2 |iM SMART II A Oligonucleotide (5'- AAG CAG TGG TAT CAA 
CGC AGA GTA CGC GGG -3'), and the final volume was adjusted to 5 i^l by 
DEPC-treated water. The reaction mixture was incubated at 70°C for 2 minutes and 
chilled on ice for 2 minutes. Reverse transcription was then performed at 42°C for 
1 hour with IX First-Strand Buffer (50 mM Tris-HCl [pH 8.3], 75 mM KCl, and 
6 mM MgCb), 2 mM Dithiothreitol (DTT), 1 mM dNTP, and 1 |il PowerScript™ 
Reverse Transcriptase. Forty microliters TE buffer was added to the first-strand 
reaction product and heated at 72°C for 7 minutes to inactivate reverse transcriptase. 
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2.3.2 Second-Strand cDNA Synthesis 
For the best results, the PCR cycling parameters were optimized. Choosing 
the optimal number of PCR cycles ensures that the double-stranded cDNA would 
remain in the exponential phase of amplification. Over-cycling of PCR reaction 
would lower the quality of cDNA template for subtraction while under-cycling 
would lower the yield of PCR product. The optimal number of PCR cycle was one 
cycle before reaching the plateau. Three sets of PCR reaction were performed with 
10 1^1 of first-strand cDNA product, IX Advantage 2 PCR Buffer (40mM Tricine-
KOH [pH 9.2]，15 mM KOAc, 3.5 mM Mg(0Ac)2, and 3.75 |ag/ml BSA), 0.2 mM 
dNTP, 0.2 [iM 5'PCR Primer IIA (5'- AAG CAG TGG TAT CAA CGC AGA GT-
3'), and IX Advantage 2 Polymerase Mix in a final volume of 100 |il. The reaction 
mixture was then subjected to 95°C denaturation for 1 minute, followed by 15 cycles 
of amplification (95°C, 30 sec; 65°C, 30 sec; 68°C, 6 min). One set of PCR reaction 
was used for determination of optimal PCR cycle of second-strand cDNA synthesis 
and other 2 sets of PCR reaction were stored at 4°C. Fifteen microliters of each PCR 
product from 15, 18, 21 and 24-cycle PCR was then analyzed on a 1.0% TAE 
agarose/EtBr gel. Two stored PCR reactions were then subjected to additional cycles 
to the optimal PCR cycle. Five microliters of each PCR product from optimal cycle 
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were analyzed by 1.0% TAE agarose/EtBr gel. Two microliters of 0.5 M EDTA were 
added to terminate the reaction. The PCR products were stored at -20°C • 
2.3.3 Column Chromatography 
Two tubes of PCR product were combined and 170 |il of phenol: choloroform: 
isoamyl alcohol (25:24:1) was added. The mixture was mixed thoroughly and 
centrifuged at 14,000 rpm for 10 minutes at room temperature for phase separation. 
The upper phase was collected and 700 of n-butanol was added to concentrate 
PCR product to 40 to 70 i^l. The mixture was centrifuged at 14,000 rpm for 1 minute 
at room temperature. The upper phase was discarded. The CHROMA SPIN-1000 
column (BD Bioscience Clontech, Palo Alto, CA) was resuspended, the column 
buffer was discarded, and 1.5 ml of IX TNE buffer (10 mM Tris-HCl [pH8.0], 
lOmMNaCl，0.1 mM EDTA) was added to the column. The flow-through was 
discarded. Another 25 [i\ of IX TNE buffer was added and allowed to completely 
drain out of the column, followed by 150 |il of IX TNE buffer. Finally, 320|il of IX 
TNE buffer was added and the eluate was collected. 
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2.3.4 Rsa I Endonuclease Digestion 
To obtain the shorter, blunt-ended double-stranded cDNA fragments, which 
are necessary for both adaptor ligation and subtraction, purified SHR, WKY and 
control skeletal muscle cDNAs were digested by 15 units of Rsa I, a four-base blunt-
ended restriction endonuclease, with IX Rsa I restriction buffer (10 mM Bis Tris 
ProPane-HCl [pH 7.0], 10 mM UgCh and 0.1 mM DTT) at 37°C for 3 hours. Eight 
microliters of 0.5 M EDTA was added to terminate the reaction. NucleoTrap® PCR 
Purification Kit (BD Bioscience Clontech, Palo Alto, CA) was used for the 
purification of Rsa I-digested cDNA. Each of the Rsa I-digested cDNAs was 
aliquoted into 2 portions. Six hundred and eighty microliters of Buffer NT2 and 17 \i\ 
of NucleoTrap suspension were added and incubated at room temperature for 
10 minutes. The mixture was centrifuged at 10,000 x g for 1 minute at room 
temperature and the supernatant was discarded. The pellet was washed with 680 |J.1 of 
Buffer NT2 followed by 680 [il of Buffer NTS. The pellet was dried for 15 minutes 
at room temperature. Fifty microliters of TE buffer [pH 8.0] were added to resuspend 
the pellet. Two portions of cDNA were combined and incubated at 50 °C for 
5 minutes. The mixture was centrifuged at 10,000 x g for 30 seconds at room 
temperature and the supernatant was collected. Fifty microliters of 4 M ammonium 
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acetate and 375 ml of 95% ethanol were added. The mixture was centrifuged at 
14,000 rpm for 20 minutes at room temperature and the supernatant was discarded. 
The pellet was washed with 500 |il 80% ethanol and air-dried for 10 minutes. The 
pellet was dissolved in 6.7 of IX TNE buffer and 1.2 jil of sample was diluted 
with 11 jil of sterile H2O. Ten microliters of diluted sample was used to assess the 
yield by UV spectrophotometry. 
2.3.5 Adaptor Ligation 
To prepare cDNA samples for adaptor ligation, 1 |il of each Rsa I-digested 
SHR and WKY cDNA was diluted with 5 |il of sterile H2O. For the control, 1 iil of 
human skeletal muscle cDNA was mixed with 5 \i\ of 150 ng/ml (t)X174/ Hae III 
Control DNA. Thus it contained 0.2% Hae Ill-digested (|)X174 and each fragment 
corresponded to about 0.02% of total cDNA. 
Each diluted tester SHR, WKY and the control skeletal muscle cDNA was 
divided into 2 portions and ligated with Adaptor 1 (5'- CTA ATA CGA CTC ACT 
ATA GGG CTC GAG CGG CCG CCC GGG CAG GT -3') and Adaptor 2R (5'-
CTA ATA CGA CTC ACT ATA GGG CAG CGT GGT CGC GGC CGA GGT -3') 
respectively. For the adaptor ligation, 2 \i\ of each diluted tester cDNA was mixed 
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with 2 |iM either Adaptor 1 or Adaptor 2R in the presence of IX Ligation Buffer 
(50 mM Tris-HCl [pH 7.8], 10 mM MgCb, 2 mM DTT, 0.05 mg/ml BSA) and 
400 units T4 DNA ligase (with 300 pM ATP) to a final volume of 10 |il. For each 
tester (SHR, WKY and skeletal muscle control), 2 |j,l of each ligation mixture of 
Adaptor 1 and 2R was mixed and ligated as unsubtracted controls. All ligation 
reactions were incubated at 16°C overnight. The ligation reactions were terminated 
by adding 1 [i\ EDTA/Glycogen Mix to a final concentration of 25 mM EDTA and 
125 |ig/ml glycogen with heat inactivation at 72°C for 5 minutes. The adaptor-ligated 
tester cDNAs were stored at -20°C. 
2.3.6 Ligation Efficiency Analysis 
PGR reaction was carried out to verify that at least 25% of the cDNAs have 
adaptors on both ends. One microliter of each diluted adaptor-ligated cDNA was 
used as template, in which Adaptor 1 and Adaptor 2R ligated cDNAs were 200-fold 
diluted while the unsubtracted control was 1000-fold diluted, mixed with IX 
Advantage 2 PGR Buffer, 0.2 mM dNTP, 0.4 jiM PGR primer 1 (5'- CTA ATA CGA 
CTC ACT ATA GGG C -3,) and G3PDH 3, Primer (5'- TCC ACC ACC CTG TTG 
CTG TA-3')，and IX Advantage 2 Polymerase Mix in a final volume of 25 |il. 
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Another PCR reaction for each ligated cDNA was performed as the above condition 
except using G3PDH 5' Primer (5'- ACC ACA GTC CAT GCC ATC AC -3') instead 
of PCR primer 1. The PCR reactions were incubated at 75°C for 5 minutes to extend 
the adaptor sequences and then subjected to 20 cycles of amplification (95°C, 30 sec; 
65°C, 30 sec; 68°C, 3 min) immediately. The PCR products were analyzed on a 1.0% 
agarose/EtBr gel run in 1X TAE buffer. 
2.3.7 First Hybridization 
For each forward (SHR - WKY) and reverse (WKY - SHR) and control 
(skeletal muscle) subtraction, 1.5 |il of each Adaptor-1 ligated tester and Adaptor-2R 
ligated tester was mixed with 1.5 [i\ of corresponding Rsa I-digested driver cDNA in 
the presence of IX Hybridization Buffer, and were referred as Hybridization Sample 
1 and 2 respectively. The reactions were overlaid with 50 |il of mineral oil, denatured 
at 98°C for 1.5 minutes, followed with 8 hours incubation at 68°C in a thermal cycler. 
After the first hybridization, without removing the reactions from the thermal cycler, 
the second hybridization was performed. 
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2.3.8 Second Hybridization 
Each 1 |il of corresponding driver cDNA was combined with Hybridization 
Buffer in IX final concentration. One microliter of the mixture was aliquoted to a 
sterile microtube and overlaid with 1 drop of mineral oil. The driver cDNA was 
incubated in a thermal cycler at 98°C for 1.5 minutes. The entire Hybridization 
Sample 2 was drawn partway into a pipette tip by micropipettor, followed with a 
small amount of air. With the same pipette, the step was repeated with 1 \i\ of freshly 
denatured driver cDNA. The entire mixture was transferred to Hybridization 
Sample 1 and mixed by pipetting up and down. The above procedure ensured that 
two hybridization samples mixed together only in the presence of freshly denatured 
driver. The hybridization samples were incubated at 68°C overnight, followed by 
adding 200^1 of dilution buffer (20 mM HEPES-HCl [pH 8.3], 50 mM NaCl, 
0.2 mM EDTA [pH 8.0]) and further heating at 68°C for 7 minutes. The samples 
were stored at -20°C. 
2.3.9 Primary PCR Amplification 
Differentially expressed cDNAs are selectively amplified by two round of 
PCR amplification. In the primary PCR amplification, only double-stranded cDNAs 
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with different adaptor sequences on each end are exponentially amplified. Seven 
PCR reactions were set up: (1) forward-subtracted SHR cDNA (S), (2) unsubtracted 
SHR control (S-c), (3) reverse-subtracted WKY cDNA (W), (4) the unsubtracted 
WKY control for the reverse subtraction (W-c), (5) subtracted control skeletal 
muscle cDNA (SM), (6) the unsubtracted skeletal muscle control for the control 
subtraction (SM-c), and (7) the PCR control subtracted cDNA (C) that was provided 
by PCR-Select cDNA Subtraction Kit (BD Bioscience Clontech, Palo Alto, CA). The 
PCR control subtracted cDNA provided a positive PCR control and contained a 
successfully subtracted mixture of Hae Ill-digested (t)X174 DNA. 
One microliter of each diluted cDNAs (both the subtracted sample and 
unsubtracted control) and PCR control subtracted cDNA were combined with IX 
Advantage 2 PCR Buffer, 0.2 mM dNTP，0.4 |iM PCR primer 1 and IX Advantage 2 
Polymerase Mix in a final volume of 25 |.il. The PCR reaction was incubated at a 
thermal cycler at 75°C for 5 minutes to "fill in" the missing strand of the adaptor, 
followed by a 27-cycle amplification (94°C, 30 sec; 66°C, 30 sec; 72°C;90 sec). The 
PCR product was analyzed on a 2.0% agarose/EtBr gel run in IX TAE buffer. 
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2.3.10 Secondary PCR Amplification 
In the secondary PCR amplification, nested PCR was performed to further 
reduce the background and enrich for the differentially expressed sequences. One 
microliter of each 10-folded diluted primary PCR mixture was subjected to 
secondary PCR amplification in the IX Advantage 2 PCR Buffer, 0.2 mM dNTP, 
0.4 laM Nested PCR primer 1 (5'- TCG AGC GGC CGC CCG GGC AGG T -3') and 
Nested PCR primer 2R (5'- AGC GTG GTC GCG GCC GAG GT -3,)，and IX 
Advantage 2 Polymerase Mix in a final volume of 25 |J.1. The PCR reactions were 
subjected to 15 cycles of PCR amplification (94�C，30 sec; 68°C, 30 sec; 72°C； 
90 sec). The PCR product was analyzed on a 2.0% agarose/EtBr gel run in IX TAE 
buffer. 
2.3.11 Subtraction Efficiency Analysis 
In order to evaluate the subtraction efficiency, the abundance of 
glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA of subtracted and 
unsubtracted samples was compared by PCR analysis. For both forward- and 
reverse-subtracted samples, 1 of 10-fold diluted secondary PCR product was 
combined with IX Advantage 2 PCR Buffer, 0.2 mM dNTP, 0.4 |iM G3PDH 5' and 
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3' primers, and IX Advantage 2 Polymerase Mix in a final volume of 30 The 
PGR reactions were subjected to 94°C for 30 seconds, followed by 33 cycles of PGR 
amplification (94°C, 30 sec; 55°C, 30 sec; 72°C； 90 sec). Five microliters of each 
PGR reaction mixtures after 18, 23, 28, 33 cycles was analyzed on a 2.0% 
agarose/EtBr gel run in 1X TAE buffer. 
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2.4 Construction of Subtracted cDNA Libraries 
The forward- and reverse-subtracted cDNAs were cloned into pT-Adv Vector 
(BD Bioscience Clontech, Palo Alto, CA) by the T/A cloning method. T/A cloning 
exploited the terminal transferase activity of thermostable DNA polymerase. During 
PCR amplification, a single deoxyadenosine (A) was added to the 3’ end of 
secondary PCR products (Clark JM, 1988). PCR products could be directly cloned 
into the pT-Adv vector with its 3' A-overhangs. 
The secondary PCR product of both forward- and reverse-subtracted cDNAs 
was subjected to final extension at 72°C for 10 minutes ligated to pT-Adv vector 
within a day. Two microliters of secondary PCR product was mixed with 50 ng 
linearized pT-Adv vector, 4.0 Weiss units of T4 DNA ligase, IX Ligation Buffer 
(6 mM Tris-HCl [pH 7.5], 6 mM MgCb，5 mM NaCl, 0.1 mg/ml BSA, 7 mM (3-
mercaptoethanol, 0.1 mM ATP, 2 mM DTT, 1 mM Spermidine) in a total volume of 
10 The ligation mixture was incubated at 14�C overnight. Besides ligation 
reactions of two subtracted cDNAs, a self-ligation control was set up as the above 
condition without an addition of cDNA. 
Two microliters of ligated product was added to 50 \i\ of TOPI OF' 
Escherichia coli competent cells with 20 mM p-mercaptoethanol. The reaction 
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mixture was incubated on ice for 30 minutes. After 30-minute incubation, heat shock 
was performed for exactly 30 seconds at 42 °C, followed by placing on ice for 
2 minutes. The transformed cells were recovered in the presence of 250 jil of SOC 
medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCh, 10 mM MgS04, and 20 mM glucose). It was shaken horizontally at 37°C for 
1 hour at 225 rpm. The transformed bacterial cells were spread onto the LBA plates 
(LB medium in 1.5% agar, 25 mg/ml X-Gal, 50 [LM IPTG, and 50|ag/ml ampicillin) 
at a suitable density for colony picking. The LBA plates were inverted and incubated 
at 37°C for at least 18 hours. The plates were shifted to 4°C for 2 to 3 hours for color 
development. White colonies were randomly picked and cultured in 100|_L1 of LBA 
medium. The LBA culture was shaken horizontally at 37°C overnight at 225 rpm. 
The bacterial culture was then stored at 4�C 
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2.5 cDNA Microarray Analysis 
2.5.1 PCR amplification of Subtracted Clones 
Bacterial culture from each subtracted clones was spun down and 0.5 )j.l of 
the supernatant was directly subjected to PCR amplification in the presence of IX 
PCR buffer (50 mM KCl, 1.5 mM MgClz, 10 mM Tris-HCl), 0.3 mM dNTP, 0.2 ^M 
Nested PCR primer 1 and 2R, and 4 units Taq DNA Polymerase to a total volume of 
100 [i\ in a 96-well plate format. The PCR reactions were subjected to 95�C 
denaturation for 1 minute, followed by 35 cycles of PCR amplification (95 °C, 40 sec; 
64°C, 40 sec; 72°C, 3 min) and a final extension at 72°C for 10 minutes. The PCR 
products were analyzed on 1 % agarose/EtBr gel run in 1X TAE buffer. 
2.5.2 Purification of PCR Products of Subtracted Clones 
GFX-96 PCR Purification Kit (Amersham Bioscience, Piscataway, NJ) was 
used for the purification of the PCR products of subtracted clones. A GFX-96 plate 
was put on top of a wash plate. Three hundred microliters of binding buffer was 
added into each well of the GFX-96 plate by multichannel pippettor. All PCR 
products were transferred to the wells of the GFX-96 plate and mixed. The GFX 
plate was centrifuged at 1800 x g for 2 minutes and the flow-through was removed. 
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The wells of the plate were then washed with 400 of wash buffer. Finally, 50 p.! of 
elution buffer was added onto the center of each well in the GFX-96 plate and 
incubated for 1 minute at room temperature. The plate was centrifuged at 1800 x g 
for 2 minutes and the purified PGR products were collected in the sample collection 
plate. All purified PGR products were then concentrated to about 20 |il by SpeedVac. 
2.5.3 Rearrangement of Subtracted Clones into cDNA Microarray Format 
Each four 96-well plates of purified DNA were relocated into a bar-coded 
384-well plate. Ten microliters of purified DNA was added to 10 \x\ DMSO to give a 
final concentration of 200 to 400 fmol/^il. All 384-well plates were stored at -20°C 
2.5.4 cDNA Microarray Fabrication 
Target DNAs were spotted onto vapor phase coated plain glass slides 
(Amersham Bioscience, Piscataway, NJ) by Generation III Array Spotter (Amersham 
Bioscience, Piscataway, NJ). Thirty-six slides were placed on the slide tray of the 
arrayer and dust was removed by blowing the slides with high-pressure nitrogen gas. 
All the 384-well plates of purified rat heart subtracted DNA and one Lucidea 
ScoreCard control plate were plated into the hotel of the arrayer. The spotting 
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process was performed at 25°C and 55% relative humidity. After spotting, the slides 
were dried inside the arrayer for 1 hour and the spotted DNA was UV-crosslinked 
under 50mJ by Spectrolinker™ (Spectronics, Westbury, NJ). The crosslinked slides 
were stored in a light-tight slide box inside a desiccator at room temperature until 
hybridization. 
2.5.5 Probe Preparation 
Total RNA was extracted from SHR and WKY rat ventricles using TRIZOL® 
Reagent as described in section 2.2.1. The RNA sample was dissolved in 20 |j.l 
DEPC-treated sterile distilled water. The RNA sample was then analyzed on a 1.0% 
TAE agarose gel and the yield of RNA was also determined by UV 
spectrophotometry at wavelength 260 nm and 280 nm. 
The cDNA probes for microarray hybridization were synthesized by using 
CyScribe First-Strand cDNA Labeling Kit (Amersham Bioscience, Piscataway, NJ). 
Twenty-five microgram of total RNA from SHR rat ventricles was mixed with 
20 |iM oligo-dT primer and mRNA spike mix (Amersham Bioscience, Piscataway, 
NJ) in a volume of 20 [i\. The mixture was incubated at 70°C for 5 minutes and then 
cooled at room temperature for 10 minutes. The reaction mixture was then placed on 
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ice and mixed with IX CyScript buffer [pH 8.3], 10 \xM DTT, 2 i^l dCTP nucleotide 
mix, 100 laM Cy3-dCTP (NEN Life Science Products, Boston, USA), and 200 units 
of CyScript reverse transcriptase. The reaction was incubated at 42°C for 1 hour. One 
hundred units of CyScript reverse transcriptase was added and incubated at 42°C for 
another 1 hour. 20 |il of 0.1 N NaOH/2 mM EDTA was added and incubated at 65°C 
for 10 minutes, and then neutralized by adding 20 |LI1 of 0.1 N HCl. For RNA sample 
of WKY, same labelling reaction was performed except using Cy5-dCTP instead of 
CySdCTP. Moreover, reverse labelling was also performed in which RNA of SHR 
and WKY rats were labelled with Cy5-dCTP and Cy3-dCTP respectively. The 
labelled probes were purified from unincorporated labelled dCTP by GFX-96 PCR 
Purification Kit as described in section 2.5.2. The purified probes were then 
concentrated by Microcon Centrifugal Filter Units (Millipore, Billerica, MA). The 
purified probes were applied into the sample reservoir of the filter devices 
respectively and centrifuged at 1000 x g for 5 to 10 minutes until the final volume of 
the cDNA probes was concentrated to about 10 |LI1. 
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2.5.6 cDNA Microarray Hybridization 
Ten microliters of each corresponding Cy3- and Cy5- labeled cDNA probes 
were mixed together with 20)0.1 hybridization solution (Amersham Bioscience, 
Piscataway, NJ), 2.8 |j.g PolyA RNA, and 40 of formamide. The hybridization 
solution was put in between the microarray slide and a 20 x 22 mm glass coverslip 
and place in a hybridization chamber in which the basement was filled up with 3X 
SSC. The hybridization was carried out at 42°C for 16 hours in an air chamber. After 
the hybridization process, the coverslip was removed and the microarray slides were 
washed with Wash lA solution (2X SSC, 0.03% SDS) at room temperature for 
5 minutes, and then Wash IB solution (2X SSC), Wash 2 solution (IX SSC) and 
finally Wash 3 solution (0.2X SSC). The microarray slide was dried by 
centrifugation at 1000 rpm for 10 minutes to remove excess fluid. 
2.5.7 Scanning cDNA Microarray Image and Data Analysis 
The microarray slides were scanned at 532nm for Cy-3 and 635nm for Cy5 
by ScanArray® 4000 scanner (PerkinElmer Life Science Products, Boston, MA). The 
scanned images of Cy3 and Cy5 were first processed using Dapple software 
version 0.86 (http://www.cse.wustl.edu/~jbuhler/research/dapple). The Cy3 and Cy5 
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intensity of processed data file was then normalized, by mean of spike mRNA, using 
Lucidea™ Microarray ScoreCard software (Amersham Bioscience, Piscataway，NJ) 
Those spots under detection limit (3 S.D. less than 48 spots of negative control) were 
excluded in all experiments and the normalized data file was used for further analysis. 
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2.6 Sequencing of Differentially Expressed Genes 
2.6.1 Dye-terminator Cycle Sequencing 
Those subtracted clones above 2 folds up-regulation or down-regulation were 
subjected to cycle sequencing by dye-terminator techniques. Based on 
dideoxyriboniicleotide (ddNTP) chain termination method (Sanger F et al, 1977; Wu 
et al, 1994), dye-terminator cycle sequencing utilized energy transfer format from the 
donor dye (fluorescein) to one of four rhodamine acceptor dyes (rhodamine 100, 
rhodamine-6-G, tetramethyl rhodamine and rhodamine X) labeled on different 
dideoxyribonucleotide (ddGTP, ddATP, ddTTP and ddCTP) terminator for signal 
detection. 
Three microliters of unpurified PGR product amplified by Nested Primer 1 
and 2R from section 2.5.1 was directly used as DNA temple for cycle sequencing, it 
was mixed with 8 [i\ of DYEnamic ET reagent premix (Amersham Bioscience, 
Piscataway, NJ), 1 |iM ofNester Primer 1 in a volume of 20 \i\. Sequencing reaction 
was performed in 96-well format for 30 cycles (95°C, 10 sec; 50°C, 15 sec; 60°C, 
60 sec). 
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2.6.2 Post-reaction Cleanup 
Ethanol precipitation was carried out as post-reaction cleanup before gel 
electrophoresis. For each reaction, 2 of 7.5 M ammonium acetate and 55 |il of 
100% ethanol were added, and centrifuged at 4,000 rpm for 30 minutes at 14°C. The 
plate was inverted and centrifuged for another 1 minute at 500 rpm on a paper towel 
to remove supernatant. The pellet was then washed with 70% ethanol and centrifuged 
at 4,000 rpm for 15 minutes at 14°C, followed by an inverted spin. The plate was air-
dried and resuspended in 20 |il of loading dye (70% form amide and 1 mM EDTA). 
The sample was stored at 4°C before gel electrophoresis analysis on MagaBACE™ 
1000 DNA sequencer (Amersham Bioscience, Piscataway, NJ) 
2.6.3 Signal Detection and Data Collection 
MagaBACE丁M 1000 DNA sequencer utilized capillary electrophoresis with 
96 capillaries. The DNA samples in 96-well plate format were automatically injected 
into linear polyacrylamide (LPA) matrix by applying voltage. The signal was 
detected based on different emission from different rhodamine dyes labeled on four 
ddNTPs terminator. After the electrophoresis, the sequencing results were exported 
and the quality index was analyzed by MegaBACE ScoreCard. 
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2.6.4 Sequencing Analysis 
The sequences of subtracted clones were searched against the non-redundant 
(NR) nucleotide sequence databases of GenBank at the National Center for 
Biotechnology Information (NCBI) using Basic Local Alignment Search Tool 
(BLAST) program. Sequence similarity identified by Standard nucleotide-nucleotide 
BLAST (BLASTN) was considered statistically significant with a minimum 
Expectation (E) value of E value is a parameter representing the number of hits 
one can "expect丨，to find by chance when searching a database of a particular size. 
The sequencing results of the highest score and matching percentage were stored in a 
database for further analysis. 
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2.7 Reverse Transcription Polymerase Chain Reaction 
Total RNAs of SHR and WKY rat ventricles were extracted using TRIZOL® 
Reagent as described in section 2.2.1, and then subjected to DNase I digestion. The 
reverse transcription was performed using ThermoScript™ RT-PCR System 
(Invitrogen丁M Life Technologies, Carlsbad, CA). Twenty-five micrograms of DNase 
I-digested RNA was mixed with 10 oligo-dT primer and 1 mM dNTP in a 
volume of 60 ^il. The mixture was incubated at 65°C for 5 minutes and placed on ice. 
The reaction was then mixed with IX cDNA synthesis buffer, 5 ^iM DTT, 200 units 
of RNase OUT™, and 75 units of ThermoScript丁^ reverse transcriptase. The 
reaction was incubated at 55°C for 1 hour and then 85°C for 5 minutes. 10 units of 
RNase H was then added to the reaction and incubated at 37°C for 20 minutes. The 
first-stand cDNA was then diluted 10 folds. The diluted cDNA templates of SHR and 
WKY were normalized before performing RT-PCR of candidate genes. The 
normalization of cDNA templates was performed by using housekeeping genes 
G3PDH and p-actin. One microliter of diluted temple was mixed with IX PCR 
buffer, 0.25mM dNTP, 0.4 |iM G3PDH-F1 (5，- ACC ACA GTC CAT GCC ATC 
ACT GCC -3，）and G3PDH-R2 (5'- TCC ACC ACC CTG TTG CTG TAG CCA -
3'), and 1.25 units of Taq DNA Polymerase. Another PCR reaction was set up as 
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same condition except using Rn-p-actin-Fl (5'- TGA GCT GCG TGT GGC CCC 
TGA G —3，) and Rn-P-actin-R 2(5'- GGG GCA TCG GAA CCG CTC ATT G -3'). 
The PGR reaction was subjected to 95°C denaturation for 1 minute, followed by 
25 cycles of amplification (95°C, 40 sec; 58°C, 40 sec; 72°C, 1 min). Five microliters 
of each PGR products from 25, 30 and 35-cycle PGR was then analyzed on a 1.0% 
TAE agarose/EtBr gel The DNA template was adjusted based on the agarose gel 
results. 
Primers for candidate genes, Voltage-dependent anion channel 1 (Vdacl), 
Protein tyrosine phosphatase 4a 1 (PTPase 4a 1), Choline transporter-like protein 1 
splice variant a (CTLla), Ryanodine receptor type II (RYR2), G protein beta 1 
subunit (rGbl) and Solute carrier family 3 member 1 (Slc3al) were designed and 
designated as VDACl-Fl (5'- GCT GGA TGG CAA GAA CGT CAA TG -3，）and 
VDAC1-R2 (5'- CAC CGG GGT TCG ATG TTC AGG A -3’)，PTP4al-Fl (5’-
GCG GCG CGG AGC TTT TAA CAG -3') and PTP4al-R2 (5'- AAG CCC TGC 
GGT GTT TGA AAT GA -3'), CTLIA-Fl (5，- CCG CCT TAT TCG TTA CCA 
CCT CG -3，）and CTL1A-R2 (5'- AGG CCC GTG CTG CAG ACT ATC A -3，)’ 
RyR2-Fl (5'- GTC GCC TTC GCC ATC AAT TTC AT -3，）and RyR2-R2 (5，- TTC 
CGA TGG CTG CTC CGT AAT GTA -3,), rGBl-Fl (5,- CTT CGT GCA GAC 
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CAG GAG CTC ATG -3，）and rGBl-R2 (AAT GGC CCC AGA AAA ATG CAC 
AA -3'), Slc3al-Fl (5'- TGC GGG GTT TAG TGA GGC CAA -3') and Slc3al-R2 
(5'- GGA GTA GCA TGC ACG GTT GGA AAT -3'). 
- 5 3 -
Materials & Methods 
2.8 Northern Blot Analysis 
2.8.1 RNA Transfer 
Total RNAs of SHR and WKY rat ventricles were extracted using TRIZOL® 
Reagent as described in section 2.2.1. The preliminary normalization of RNA 
samples was achieved by visual examination and densitometric quantification of 28S 
and 18S ribosomal RNA. The normalized RNA samples and digoxigenin (DIG)-
labeled RNA molecular weight marker I (Roche Applied Science, Mannheim, 
Germany) were denatured at 65°C for 10 minutes in RNA loading buffer and placed 
on ice immediately. The denatured RNA samples were loaded on a 1% 
agarose/formaldehyde gel run in IX MOPS buffer at 40V. The RNA gel was 
equilibrated in 20X DEPC-treated SSC to remove formaldehyde. RNA was then 
transferred to Nytran® nylon membrane using TurboBlotter™ (Schleicher & Schuell 
Bioscience, Keene, NH) in the presence of transfer buffer, DEPC-treated 20X SSC, 
at room temperature overnight. RNA was UV-crosslinked to the nylon membrane 
under 50 mJ by Spectroliiiker™. The UV-crosslinked nylon membrane was 
equilibrated in DEPC-H2O to remove 20X SSC. 
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2.8.2 Probe Labeling 
PCR DIG Probe Synthesis Kit (Roche Applied Science, Mannheim, Germany) 
was used for DIG-labeled cDNA probe synthesis. One microliter of cDNA temples 
from SHR and WKY rats was mixed with IX PCR buffer (with 1.5 mM MgCb), IX 
PCR DIG probe synthesis mix (200 i^M dATP, 200 i^M dCTP, 200 [iU dGTP, 
130 |iM dTTP, and 70 \iM DIG-11-dUTP [pH 7.0]), 0.25 jiM of forward and reverse 
primers of candidate genes described in section 2.7, and 2.6 units of the Expand High 
Fidelity enzyme mix. An unlabeled PCR control was set up with same condition 
except using 200 jiM dNTP instead of PCR DIG probe synthesis mix. The probe 
reaction mixture and unlabeled control were subjected to 95 °C for 2 minutes, 
followed by a 35-cycle PCR amplification (95°C, 30 sec; 60°C, 40 sec; 72°C, 40sec) 
and a final extension at 72°C for 10 minutes. The DIG-labeled probe and unlabeled 
control were analyzed on a 1.0% TAE agarose/EtBr gel. 
2.8.3 Hybridization 
The RNA blot was pre-hybridized in 20 ml DIG Easy Hyb buffer (Roche 
Applied Science, Mannheim, Germany) at 50°C for 30 minutes. The DIG-labeled 
probe was denatured at 95 °C for 10 minutes and placed on ice. Seventy-five 
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nanograms of probe was added to 3 ml pre-warmed DIG Easy Hyb. The probe/DIG 
Easy Hyb mixture was added to the membrane and hybridized at 50°C overnight. 
The RNA blot was washed twice, with shaking, in low stringency wash buffer 1 (2X 
SSC and 0.1% SDS) at room temperature for 5 minutes per wash. The blot was then 
washed twice, with shaking, in pre-warmed high stringency wash buffer 2 (O.IX SSC 
and 0.1% SDS) at 50°C for 15 minutes per wash. 
2.8.4 Chemiluminescent Detection 
The RNA blot was equilibrated in washing buffer (100 mM maleic acid, 
150 mM NaCl [pH 7.5], 0.3% Tween® 20) for 5 minutes. The blot was blocked with 
IX blocking buffer (1% Blocking reagent, 100 mM maleic acid, 150 mM NaCl 
[pH 7.5]) at room temperature for 30 minutes. The probe was then incubated in Anti-
Digoxigenin-AP (Roche Applied Science, Mannheim, Germany) antibody solution 
(75 mU/ml; 1:10,000 in blocking buffer) for 1 hour. The RNA blot was washed twice 
in wash buffer (100 mM maleic acid, 150 mM NaCl [pH 7.5], 0.3% Tween® 20) at 
room temperature for 15 minutes per wash. The blot was equilibrated in detection 
buffer (100 mM Tris-HCl and 100 mM NaCl [pH 9.5]). The blot was then placed on 
transparency and 1 ml of CDP-Star solution (Roche Applied Science, Mannheim, 
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Germany), 100-fold diluted in detection buffer, was applied to the blot. The blot was 
covered with transparency, incubated in an X-ray cassette at room temperature for 5 
minutes and exposed to a film for signal detection. 
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Chapter 3: Results 
3.1 Suppression Subtractive Hybridization 
3.1.1 The Optimal Cycle for SMART cDNA Synthesis 
For the best results from the subtraction steps, the PGR cycling parameters 
for SMART cDNA synthesis were optimized. The optimal PGR cycle was chosen to 
ensure that double-stranded cDNA remained in the exponential phase of 
amplification. When the yield of PGR products stopped increasing with more cycles, 
the reaction has reached the plateau. Overcycled cDNA would deteriorate the quality 
of template for cDNA subtraction while undercycling would result in a lower yield of 
PGR products. The optimal cycle for the SMART cDNA synthesis was 1 cycle 
before the plateau was reached. The optimal cycles of SHR and WKY cDNA 
synthesis were determined as 21 and 19 respectively (Figure 7). In general, cDNAs 
synthesized from mammalian total RNA should appear as a moderately strong smear 
from 0.5 to 6 kb with distinct bands. The number and position of the bands would be 
different between SHR and WKY samples. Furthermore, cDNA prepared from 
mammalian tissue source such as ventricular tissues might not display bright bands 
due to the very high complexity of mRNA. 
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Figure 7 Analysis for optimal PCR cycles. 
Lanes 1 to 4: PCR products of SHR cDNA at 15, 18,21 and 24 cycles respectively. 
Lanes 5 to 8: PCR products of WKY cDNA at 15，18，21 and 24 cycles respectively. 
Lane M: 1-kb DNA ladder marker 
Lane 1 2 3 4 M 5 6 7 8 
•�bp ~ • ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H I I P I H 
2000 bp Z Z ^ ^ ^ ^ ^ ^ H 
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3.1.2 Adaptor Ligation Efficiency 
In order to verify that cDNAs were successfully ligated with either Adaptors 
1 or 2R, ligation efficiency analysis for tester cDNA of SHR and WKY, and control 
skeletal muscle cDNA were performed. Ligated products were amplified using either 
a pair of gene-specific primers (G3PDH 3’ and 5' Primers) or gene-specific primer 
(G3PDH 3' Primer) and PCR Primer 1. For the tester cDNAs, the PCR products 
amplified using G3PDH 3，and 5' Primers, representing the total amount of G3PDH 
transcripts, were about 0.45 kb. On the other hand, the PCR products amplified using 
G3PDH 3，Primer and PCR primer 1，representing G3PDH transcripts ligated with 
adaptors, were about 1.2 kb (Figure 8). While for the skeletal muscle control cDNA, 
the PCR product amplified using G3PDH 3' Primer and PCR primer 1 was about 
0.75 kb because human G3PDH cDNA contains an Rsa I restriction site. By 
comparison of band intensities between adaptor-ligated G3PDH and total G3PDH 
transcripts, both Adaptor 1 and 2R were shown successfully ligation to cDNAs of 
SHR, WKY and skeletal muscle control cDNAs (Table 2). For skeletal muscle 
control, the band intensity of adaptor-ligated G3PDH was a bit higher than that of 
total G3PDH that was due to inefficiency of PCR amplification. However, the 
ligation efficiency was sufficient since the band of ligated G3PDH was strong. 
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Figure 8 Ligation efficiency analysis by PCR amplification. 
Panel A: Ligation efficiency analysis of SHR tester cDNAs. Panel B: Ligation 
efficiency analysis of WKY tester cDNAs. Panel C: Ligation efficiency analysis of 
control skeletal muscle cDNAs. For each panel, lane 1 represents PCR product of 
Adaptor 1-ligated cDNA amplified using G3PDH 3' and 5' primers; lane 2 
represents PCR product of Adaptor 1-ligated cDNA amplified using G3PDH 3’ 
primer and PCR primer 1; lane 3 represents PCR product of Adaptor 2R-ligated 
cDNA amplified using G3PDH 3’ and 5' primers; lane 4 represents PCR product of 
Adaptor 2R-ligated cDNA amplified using G3PDH 3，primer and PCR primer 1; and 
lane M represents 1 kb DNA ladder marker. 
Panel A Panel B 
1 2 M 3 4 1 2 M 3 4 
|H[ 
^ ~ 1.2 kb ~ ^ 
^ ~ 0 . 4 5 kb ~ ^ 
Panel C 
1 2 M 3 4 
• 
^ _ 0.75 
^ ~ 0.45 kb 
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Table 2 Determination of ligation efficiency by band intensities. 
Ligation efficiencies of each tester and control cDNAs are presented by percentages 
of G3PDH transcript ligated with each adaptor. 
Adaptor 1 Adaptor 2R — 
SHR tester cDNA 
G 3 P D H 3 ' + 5 ' 1 2 7 8 2 1 5 9 4 3 
Band Intensity g 3 P D H 3 ' + PCR primer 1 8 6 6 8 8 9 4 8 
Ligation Efficiency 67.8% 56.1% 
WKY tester cDNA 
. G3PDH3，+ 5, 19173 18035 
Band Intensity G3PDH 3’ + PCR primer 1 10417 11887 
Ligation Efficiency 54.3% 65.9% 
Control Skeletal Muscle cDNA 
G 3 P D H 3 ’ + 5’ 8 3 8 0 5 3 3 0 
Band Intensity g3PDH 3 ' + PCR primer 1 5401 6 0 4 1 
Ligation Efficiency 64.5% 113.3% 
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3.1.3 Primary and Secondary PGR Amplification of Subtracted cDNA 
During primary PGR amplification, double-stranded cDNAs with Adaptor 1 
and 2R on each end were exponentially amplified. The primary PGR products of 
subtracted and unsubtracted samples appeared as smears from 0.2 to 3 kb, with or 
without distinct bands. For the PGR subtracted control cDNA, some weak bands 
appeared which were corresponding to the (\)X\74/Hae III fragments. The skeletal 
muscle subtracted cDNA, however, showed the corresponding <\)Xn4/Hae III 
fragments only after the secondary PGR (Figure 9). 
Nested PGR was then performed to further reduce the background and the 
differentially expressed sequences were enriched. The patterns of secondary PGR 
products were similar to that of primary PGR products. The subtracted and 
unsubtracted PGR products appeared as smears with or without distinct bands. The 
secondary PGR product of the subtracted skeletal muscle sample contained mostly 
DNA fragments corresponding to the (^X\14/Hae III fragments, which showed a 
successful subtraction in the skeletal muscle control (Figure 10). However, a slight 
mobility shift was observed compared with the original, digested (t)X174 in the PGR 
subtracted control due to the adaptor sequences on both ends of DNA fragments. 
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Figure 9 Agarose gel electrophoresis of primary PCR of subtracted and 
unsubtracted samples. 
Lane 1: Primary PCR product of subtracted SHR cDNA. Lane 2: Primary PCR 
product of unsubtracted SHR cDNA. Lane 3: Primary PCR product of subtracted 
WKY cDNA. Lane 4: Primary PCR product of unsubtracted WKY cDNA. Lane 5: 
Primary PCR product of subtracted skeletal muscle cDNA containing 0.2% 
^X174/Hae Ill-digested DNA. Lane 6: Primary PCR product of unsubtracted skeletal 
muscle control containing 0.2% ^Xl74/Hae Ill-digested DNA. Lane 7: Primary PCR 
product of PCR control subtracted DNA. Lane M: 1 kb DNA ladder marker. 
M 1 2 3 4 5 6 7 
1.3 kb 
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Figure 10 Agarose gel electrophoresis of secondary PCR of subtracted and 
unsubtracted samples. 
Lane 1: Secondary PCR product of subtracted SHR cDNA. Lane 2: Secondary PCR 
product of unsubtracted SHR cDNA. Lane 3: Secondary PCR product of subtracted 
WKY cDNA. Lane 4: Secondary PCR product of unsubtracted WKY cDNA. Lane 5: 
Secondary PCR product of subtracted skeletal muscle cDNA containing 0.2% 
(^X174/Hae Ill-digested DNA. Lane 6: Secondary PCR product of unsubtracted 
skeletal muscle control containing 0.2% ^X\74/Hae Ill-digested DNA. Lane 7: 
Secondary PCR product of PCR control subtracted DNA. Lane M: 1 kb DNA ladder 
marker. 
M 1 2 3 4 5 6 7 
kb 
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3.1.4 Subtraction Efficiency 
The subtraction efficiencies of subtracted SHR- and WKY- cDNAs were 
demonstrated by reduction of G3PDH abundance in the subtracted secondary PGR 
product compared to that of unsubtracted one. For SHR cDNA, G3PDH PGR 
product of subtracted cDNA appeared at 24 cycles while that of unsubtracted cDNA 
appeared after 21 cycles. For WKY cDNA, G3PDH PGR product of subtracted 
cDNA at 24 cycles while that of unsubtracted cDNA was observed after 18 cycles. 
Subtraction efficiency analysis demonstrated the common cDNA sequences were 
eliminated while the subtraction efficiency of WKY cDNA was higher than that of 
SHR cDNA (Figure 11). 
- 6 6 -
Results 
Figure 11 Subtraction efficiency analysis by detection of G3PDH transcript. 
Panel A: Subtraction efficiency of SHR cDNA. Panel B: Subtraction efficiency of 
WKY cDNA. Lane 1 to 4: PCR products of subtracted cDNA at 15, 18, 21 and 24 
cycles. Lane 5 to 8: PCR products of unsubtracted cDNA at 15, 18, 21 and 24 cycles. 
Panel A 
1 2 3 4 5 6 7 8 
m^umimimQi 0.45 kb 
Panel B 
1 2 3 4 5 6 7 8 
0.45 
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3.2 Subtracted cDNA Libraries 
Blue-white screening was performed in order to identify the colonies in 
which subtracted cDNA was successfully ligated into the T/A cloning vector. One of 
the LBA plates from each subtracted libraries and the LBA plate of self-ligation 
negative control were counted. The self-ligation negative control verified that the pT-
Adv vector contained 3' T-overhangs. Loss of the T-overhangs results in blunt-end 
ligation and disruption of the lacZa reading frame. False whites colonies would 
result. Normally, lees than 5% of white colony-forming units (cfu) should be 
observed. For self-ligation negative control, only 1.5% of white cfu were observed 
(Table 3). 
Table 3 Blue-white screening of subtracted cDNA libraries. 
White cfu Blue cfu % White cfu 
SHR subtracted cDNA library 60.1% 
WKY subtracted cDNA library 203 130 61.0% 
Self-ligation negative control 2 126 1.5% 
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3.3 cDNA Microarray Analysis 
3.3.1 Isolation and Amplification of Subtracted cDNA Clones. 
Five hundred white colonies from each subtracted cDNA libraries, designated 
as SLOOl to SL500 and WLOOl to WL500 respectively, were picked, cultured and 
amplified. Only the PCR products of subtracted clones showing single band on 1% 
agarose/EtBr gel were purified and spotted on microarray slides. For the microarray 
fabrication, 463 and 449 of SHR- and WKY-subtracted clones were spotted on the 
microarray slides respectively. SHR-subtracted clones represent genes that are 
up-regulated in hypertensive ventricle while WKY-subtracted clones represent those 
showing down-regulation. 
3.3.2 Microarray Scanning and Analysis 
The microarray of differentially expressed genes in rat hypertension was 
hybridized with fluorescent labeled probes of SHR and WKY cDNAs. Another set of 
microarray hybridization was also performed with the probes labelled in a reversed 
manner. Microarray analysis was repeated 2 times for more accurate results. The 
hybridized cDNA microarrays were scanned at 532nm (Cy-3) and 635nm (Cy5). The 
Cy3- and Cy5-scanned images were superimposed, and one of the overlapped images 
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was shown (Figure 12). The green spots represented those with higher gene 
expression levels in Cy3-labeled cDNA while the red spots represented those with 
higher gene expression levels in Cy5-labeled cDNA. For those with similar gene 
expression level in both Cy-3 and Cy-5 labeled cDNAs, yellow colour was observed. 
The Cy3- and Cy5-scanned images were analyzed by Dapple 0.86. Dapple is 
an intensity quantification software for microarray data analysis. It identified the 
spot area and quantified the fluorescent intensity of spots automatically. The area 
of particular spots was adjusted manually. The data file was then exported and 
analyzed by Lucidea™ Microarray ScoreCard. Based on the fluorescent signals of 
spike RNA control, normalization between Cy3 and Cy5 signals was done. 
LucideaTM Microarray ScoreCard calculated the standard deviation, normalized 
fluorescent intensity, un-normalized logarithm ratio of Cy3 to Cy5 (ULR), and the 
normalized logarithm ratio of Cy3 to Cy5 (NLR). Normalization is necessary for 
accurate calculation in microarray analysis. We defined the threshold level for 
NLR as either above 0.3 or below 0.3, NLR values outside this range represented 
the expression level of particular clone was at least 2-fold up-regulated or 
down-regulated between SHR and WKY cDNAs. Spots showing NLR value in 
between 0.3 and -0.3 was regarded as fairly constant in expression level. 
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The linear graph of microarray data (Figure 13) as well as the logarithm 
graphs of both un-normalized and normalized data (Figure 14) were plotted to show 
the differential ratio distribution of subtracted libraries. The results showed that 161 
(34.7%) out of 463 clones were consistently up-regulated (Table 4) while 156 
(35.6%) out of 449 clones were down-regulated (Table 5). These clones were 
selected for identification and further confirmation. The remaining clones were either 
not quantifiable or shown as NLR value in between 0.3 and -0.3 in microarray 
analysis. 
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Figure 12 The image of cDNA microarray. 
This figure shows the microarray image obtained from the Dapple 0.86 microarray 
analysis program. 
• H H B H H 
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Figure 13 Linear plot of microarray results. 
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Figure 14 Logarithm plots of microarray results showing the differential 
expression of subtracted clones.. 
Graph 14a: Logarithm plot of un-normalized data of microarray results 
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Table 4 Subtracted clones showing up-regulation in microarray analysis 
""“Clone No. NLR Clone No. NLR S.D. 
SLOW O ! ^ 07I80 SL086 0.536 0.092 
SL004 0.414 0.005 SL087 0.342 0.040 
s u m 0.632 0.053 SL090 0.959 0.003 
SL012 0.579 0.088 SL091 0.400 0.163 
SL013 0.785 0.100 SL093 0.712 0.089 
SL014 0.394 0.047 SL094 0.313 0.020 
SL015 0.545 0.041 SL095 0.470 0.146 
SL017 0.834 0.339 SL097 0.426 0.005 
SL027 0.908 0.130 SL099 0.326 0.042 
SL032 0.361 0.007 SL102 0.392 0.029 
SL034 0.776 0.327 SL103 0.336 0.016 
SL036 0.401 0.111 SL105 0.489 0.122 
SL038 0.309 0.008 SL106 0.411 0.083 
SL039 0.321 0.022 SL107 0.379 0.004 
SUMO 0.314 0.061 SL109 0.378 0.039 
SL042 0.650 0.239 SLllO 0.657 0.049 
SL048 0.333 0.036 SLl l l 0.311 0.021 
SL049 0.354 0.036 SL112 0.366 0.149 
SL051 0.341 0.024 SL117 0.482 0.003 
SL052 0.308 0.015 SL119 0.696 0.039 
SL053 0.399 0.092 SL120 0.482 0.052 
SL057 0.484 0.180 SL123 0.640 0.008 
SL062 0.429 0.119 SL124 0.401 0.164 
SL063 0.497 0.119 SL125 0.368 0.007 
SL064 0.621 0.007 SL127 0.406 0.196 
SL066 1.380 0.129 SL128 0.379 0.039 
SL070 0.327 0.016 SL130 0.402 0.029 
SL072 0.336 0.016 SL134 0.386 0.069 
SL074 0.323 0.009 SL135 0.502 0.061 
SL075 0.618 0.034 SL140 0.397 0.047 
SL076 0.527 0.033 SL141 0.382 0.043 
SL077 0.521 0.034 SL143 0.338 0.043 
SL082 0.513 0.033 SL147 0.778 0.328 
SL083 0.346 0.008 SL149 0.487 0.083 
SL085 0.605 0.087 SL155 0.693 。膽 
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""“Clone No. NLR S!D! ""“Clone No. NLR S!D! 
SL156 0.793 SL290 0.359 0.100 
SL168 0.578 0.037 SL291 0.377 0.010 
SL170 0.377 0.002 SL292 0.370 0.033 
SL171 0.307 0.004 SL294 0.365 0.032 
SL172 0.829 0.095 SL296 0.457 0.057 
SL176 0.695 0.059 SL299 0.956 0.003 
SL179 1.178 0.203 SL301 0.314 0.009 
SL183 0.544 0.247 SL304 0.789 0.094 
SL187 0.456 0.057 SL307 0.415 0.007 
SL189 0.319 0.027 SL311 0.380 0.113 
SL193 0.868 0.066 SL333 0.820 0.261 
SL195 0.425 0.011 SL335 0.515 0.054 
SL197 0.356 0.059 SL336 0.326 0.016 
SL202 0.403 0.036 SL340 0.467 0.029 
SL207 0.427 0.071 SL342 0.471 0.059 
SL210 0.363 0.062 SL345 0.357 0.059 
SL211 0.515 0.064 SL348 0.381 0.049 
SL212 0.454 0.105 SL357 0.320 0.005 
SL220 0.332 0.044 SL361 0.617 0.092 
SL230 0.331 0.038 SL369 0.466 0.026 
SL232 0.466 0.006 SL373 0.493 0.165 
SL241 0.391 0.035 SL374 0.572 0.199 
SL243 0.498 0.136 SL375 0.329 0.014 
SL244 0.401 0.028 SL376 0.659 0.049 
SL250 0.482 0.084 SL380 0.368 0.001 
SL255 0.362 0.017 SL383 0.335 0.013 
SL256 0.496 0.086 SL387 0.347 0.057 
SL262 0.895 0.087 SL388 0.440 0.131 
SL264 0.351 0.015 SL391 0.784 0.194 
SL266 0.318 0.012 SL392 0.349 0.042 
SL272 0.782 0.194 SL393 0.519 0.075 
SL273 0.314 0.006 SL402 0.367 0.038 
SL275 1.122 0.118 SL404 0.359 0.012 
SL280 0.700 0.184 SL407 0.823 0.078 
SL281 0.394 0.190 SL411 0.456 0.018 
SL285 0.428 0.002 SL414 0.369 0.039 
SL289 0.359 0.142 SL415 0.818 0.125 
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Clone No. NLR 
SL416 0.432 0.093 
SL420 0.370 0.054 
SL436 0.424 0.013 
SL441 0.378 0.104 
SL443 0.677 0.101 
SL458 0.559 0.095 
SL466 0.339 0.044 
SL467 0.396 0.056 
SL469 0.582 0.053 
SL470 0.384 0.050 
SL471 0.374 0.028 
SL472 0.646 0.184 
SL473 0.599 0.090 
SL477 0.497 0.058 
SL480 0.687 0.095 
SL490 0.404 0.112 
SL496 0.700 0.008 
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Table 5 Subtracted clones showing down-regulation in microarray analysis 
Clone No. NLR s l l ""”Clone No. NLR s!d! 
WLOOl 0.027 WL134 0.328 0.002 
WL002 0.363 0.034 WL136 0.368 0.038 
WL005 0.314 0.020 WL138 0.337 0.060 
WLOlO 0.702 0.185 WL143 0.768 0.202 
WL016 0.401 0.119 WL146 0.513 0.054 
WL018 0.323 0.025 WL149 0.546 0.095 
WL027 0.512 0.059 WL153 0.474 0.145 
WL035 0.638 0.008 WL157 0.314 0.015 
WL037 0.444 0.040 WL159 0.543 0.040 
WL040 0.702 0.008 WL160 0.365 0.149 
WL050 0.433 0.094 WL161 0.633 0.054 
WL051 0.406 0.040 WL162 0.442 0.040 
WL052 0.759 0.095 WL164 0.399 0.119 
WL053 0.382 0.032 WL174 0.368 0.033 
WL055 0.415 0.074 WL176 0.678 0.107 
WL059 0.394 0.080 WL177 0.359 0.058 
WL074 0.303 0.005 WL180 0.371 0.040 
WL075 0.375 0.046 WL186 0.376 0.104 
WL084 0.679 0.050 WL188 0.443 0.032 
WL087 0.441 0.032 WL189 0.348 0.138 
WL088 0.516 0.064 WL191 0.391 0.064 
WL091 0.584 0.053 WL196 0.468 0.006 
WL092 0.412 0.023 WL197 0.368 0.081 
WL095 0.319 0.049 WL198 0.442 0.027 
WL098 0.529 0.033 WL199 0.469 0.059 
WL103 1.084 0.003 WL200 0.615 0.052 
WL106 0.623 0.089 WL201 0.315 0.015 
WL115 0.354 0.034 WL202 0.619 0.093 
WL116 0.391 0.062 WL203 0.513 0.059 
WL117 0.358 0.099 WL204 0.615 0.046 
WL118 0.565 0.208 WL206 0.384 0.078 
WL124 0.366 0.001 WL211 0.747 0.021 
WL125 0.821 0.202 WL212 0.401 0.129 
WL126 0.370 0.101 WL214 0.710 0.177 
WL130 0.371 0.039 WL217 0.680 0.179 
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~~Clone No. NLR S ^ “ C l o n e No. NLR s!D! 
WL219 0.848 0.139 WL298 0.319 0.097 
WL222 0.580 0.037 WL300 0.474 0.081 
WL226 0.397 0.126 WL302 0.793 0.173 
WL231 0.771 0.011 WL309 0.710 0.003 
WL232 0.613 0.052 WL310 0.415 0.051 
WL233 0.429 0.205 \VL311 0.621 0.230 
WL237 0.315 0.061 WL314 0.417 0.176 
WL240 0.398 0.046 WL316 0.350 0.138 
\VL241 0.472 0.048 WL317 0.435 0.137 
WL243 0.856 0.210 WL319 0.350 0.106 
WL245 0.988 0.003 WL328 0.613 0.046 
WL246 0.354 0.169 WL336 0.309 0.037 
WL247 0.846 0.208 WL336 0.305 0.196 
WL248 0.425 0.005 WL339 0.332 0.012 
WL250 0.721 0.050 WL341 0.712 0.004 
WL251 0.323 0.007 WL344 0.766 0.129 
WL253 0.376 0.010 WL348 0.306 0.015 
WL255 0.517 0.047 WL351 0.346 0.022 
WL257 0.724 0.001 WL352 0.436 0.058 
WL258 0.325 0.016 WL353 0.544 0.095 
WL263 0.354 0.100 WL356 0.318 0.002 
WL263 0.338 0.045 WL361 0.334 0.012 
WL265 0.338 0.040 WL363 0.656 0.057 
WL265 0.334 0.038 WL368 0.349 0.045 
WL267 0.985 0.003 WL370 0.837 0.092 
WL273 0.369 0.102 WL372 0.543 0.246 
WL279 0.501 0.098 WL377 0.357 0.010 
WL280 0.362 0.027 WL387 0.391 0.035 
WL282 0.395 0.191 WL388 0.332 0.039 
WL283 0.714 0.174 WL389 0.774 0.144 
WL286 0.396 0.146 WL390 0.379 0.058 
WL287 0.745 0.303 WL391 0.341 0.040 
WL288 0.396 0.080 WL393 0.698 0.039 
WL290 0.414 0.184 WL394 0.426 0.011 
WL291 0.619 0.007 WL396 0.464 0.026 
WL296 0.319 0.002 WL417 0.831 0.088 
WL297 0.387 0.010 WL423 0.407 0.196 
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Clone No. NLR S ^ 
WL430 0.310 0.009 
WL441 0.379 0.002 
WL452 0.770 0.203 
WL453 0.382 0.032 
WL455 0.331 0.090 
WL456 0.310 0.037 
WL460 0.512 0.032 
WL472 0.310 0.094 
WL475 0.415 0.074 
WL481 0.303 0.005 
WL488 0.394 0.080 
WL499 0.375 0.046 
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3.4 Sequencing Results of Subtracted cDNA Clones 
After cDNA microarray analysis, the subtracted clones showing differential 
expression were subjected to sequencing. From the results, 161 SHR-subtracted and 
156 WKY-subtracted clones have obtained. Total 225 (71.0%) out of 317 sequences 
were matched with known genes, 73 (23.0%) sequences were matched with ESTs 
only, while 19 (6.0%) sequences were unmatched with any entries in the 
non-redundant database at NCBI and classified as novel genes (Table 6). The 
up-regulated and down-regulated candidate genes were summarized with their 
accession numbers, redundancies in the subtracted clones as well as the differential 
ratios determined by microarray analysis (Table 7 and Table 8). 
Table 6 Sequencing summary of ESTs showing differential expression. 
“ SHR-subtracted ESTs WKY-subtracted ESTs 
Match with know genes 109 (67.7%) 116 (74.4%) 
Match with ESTs only 41 (25.5%) 32 (20.5%) 
No database match 11 (6.8%) 8 (5.1%) 
Total 161 (100%) 156 (100%) 
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Table 7 List of up-regulated genes 
Genes Accession No. No. of Clones Differential Ratio 
Voltagc-dcpcndcnt anion channel 1 (Vdacl) NM_031353 16 6.43 
Protein tyrosine phosphatase 4al (PTPasc 4al) NM_031S79 13 4.97 
Choline transporter-like protein 1, splice variant a (CTLla) AJ420809 10 4.33 
Cytokine inducible SH2-containing protein 2 (Cish2) NM_058208 5 4.11 
Striatin, calmodulin binding protein 3 (STRN3) XM_030180 5 3.15 
Mss4 protein X70496 5 2.77 
TRAF-binding protein domain protein (TRABID) AJ252060 4 3.95 
G protein-gated K+ channel subunit 2 (Kcnj6) AF410425S3 4 3 59 
Kruppel-like factor 9 (Klf9) NM_057211 4 3.39 
Guanine nucleotide exchange factor (Larg) AF467766 4 2.28 
Ras suppressor protein 1 (RSUl) BC003827 3 4 36 
Eukaryotic translation initiation factor 2C, 1 (EIF2C1) NM_012199 3 3.35 
Voltage-dependent anion channel 2 (Vdac2) NM_031354 2 3 93 
Activin A receptor, type 1 (ACVRl) XM_050512 2 3 18 
UDP glucuronosyltransferase gene M74439 2 3 07 
Histamine N-methyltransferase (HNMT) AB007833 2 2.49 
Ribosomal protein S19 X51707 2 2.46 
Mitochondrial cytochrome c oxidase subunit Va (Cox5A) X15030 2 2.41 
Transcription factor S0X3 (Sox3) AF434675 2 2.25 
RAB6A, member RAS oncogene family (RAB6A) XM_035122 2 2.18 
3 beta-hydroxysteroid dehydrogenase type 11 (3Beta-HSD II) S63167 1 6.08 
Bcta-carotene 15, 15'-dioxygenase (Bcdo) NM_053648 1 4.03 
Golgi SNAP receptor complex member 1 (Gosrl) NM_053584 1 3.43 
Hephaestin (Hepli) NM_133304 1 3.37 
Hypothetical protein MGC2454 AC007991 1 3.32 
Matrix metalloproteinase 9 (MMP9) API69244 1 3.26 
Mitochondrial NADH dehydrogenase subunit 1 (ndl) X07479 1 3.13 
Pre-mtHSP70 mRNA S75280 1 2,66 
Ornithine decarboxylase 1 (ODCl) BC025296 1 2.51 
Phosphatidylinositol glycaii, class L (PIG-L) D88364 1 2.41 
HLA-B associated transcript 5 (BATS) AF193047 1 2.40 
HBxAg transactivated protein 2 (XTP2) XM—043678 1 2.39 
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Genes Accession No. No. of Clones Differential Ratio 
Proteasome (prosome, macropain) subunil, alpha type 5 (PsmaS) NM_017282 1 2 34 
beta-2-microgIobulin XI6956 1 2 22 
Succinate-Coenzyme A ligase, ADP-forming, beta subunit (Sucla2) AF058955 1 2 20 
Far upstream element (FUSE) binding protein 3 (FUBP3) XM_033327 1 2 09 
Transmembrane 9 superfamily member 2 (Tm9sf2) NM_080556 1 2 06 
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Table 8 List of up-regulated ESTs 
Accession No. No. of Clones Differential Ratio 
AJ250192 3 2 . 3 6 
AF060511 2 2 . 5 1 
AC087775 2 2 . 4 4 
NM_053516 2 2 . 3 7 
AC090529 2 2 . 3 3 
Y17323 2 2.18 
AC087102 2 2 . 1 4 
XM_036284 1 6 . 8 3 
AK003152 1 6 . 6 5 
AL645857 1 6 . 0 9 
BC021494 1 3 . 0 4 
AC087233 1 2 . 7 5 
BC009142 1 2 . 6 7 
AC090513 1 2 . 5 9 
BC005609 1 2 . 5 3 
AC026723 1 2 . 5 3 
AK007400 1 2 . 4 6 
AF271776 1 2 . 3 8 
AF115770 1 2 . 3 3 
AJ298228 1 2 . 3 3 
AC087367 丨 2 . 3 2 
AL035594 1 2 . 2 3 
AJ279852 1 2 . 1 9 
AC078845 1 2 . 1 6 
AF089815 ‘ 
BC025529 丨 2.13 
AF333038 1 2 . 1 2 
ACO18693 1 2 . 1 2 
Y17322 1 2 . 1 0 
AC006031 1 2 . 0 6 
AJ293848 1 2 . 0 6 
NM_133942 1 2 . 0 5 
AL354702 1 丄 0 4 
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Table 9 List of down-regulated genes 
Genes Accession No. No. of Clones Differential Ratio 
Ryanodine receptor type II (RYR2) I丨95157 14 6.14 
G protein betal subunit (rGbl) U88324 4.44 
Solute carrier family 3, member 1 (Slc3al) NIVI_017216 U 5.69 
Concentrative Na+ nucleoside cotransporter (CNT2) AY029302 8 3.10 
CyclinGl (Ccngl) NM_012923 6 2.26 
ATPase, transporting (vacuolar proton pump), beta isoform 2 (Atp6b2) NM_057213 5 3.46 
Two pore domain potassium channel KCNK6 (Kciik6) AF158234 5 2.28 
14-3-3 protein epsilon isoform M84416 5 4.10 
Heterogeneous nuclear ribonucleoprotein K (Hnrpk) NM_057141 4 3.16 
Follistatin-related protein (Fstl) NM_008047 4 2.07 
Karyopherin (importin) alpha 2 (Kpna2) NM_053483 3 3.67 
Dopamine receptor D1 (DRDl) AJ005433 3 2 49 
Unr protein (unr) NM_054006 3 2.06 
Developmentally regulated GTP binding protein 丨（Drgl) NM_007879 2 4.55 
Connexin31 (Cx31) AF288667 2 3.11 
(N6-adenosine)-methyltransferase gene AF283992 2 2.86 
Nuclear receptor subfamily 1, group H, member 4 (NR1H4) NM 021745 2 2 82 
Carnitine deficiency-associated protein(Cdv3) AF4M107 2 2.66 
Protein kinase (cAMP-dependent) inhibitor gamma (PKIG) XM_009516 2 2.41 
Cholesterol 7-alpha-hydroxylase (CYP7) gene U01962 2 2.41 
Honieodomain-only protein (HOP) AB019573 2 2.39 
Tubby like protein 1 (Tulpl) AF105711 2 2.25 
Pyruvate dehydrogenase kinase, isoenzyme 1 BC025480 2 2.14 
Hepatocarcinogenesis-related transcription factor (HTF) AB030238 2 2.04 
Splicing factor, arginine/serine-rich 3 (SFRS3) X91656 2 2.04 
PR domain containing 1, with ZNF domain (PRDM1) U05343 ' 5.03 
Homolog of yeast nuclear protein localization 4 (Npl4) NM一080577 1 4.34 
Growth hormone (presomatotropin) V01239 3.25 
p300/CBP-associated factor(PCAF) BC019722 丨 2.78 
Serum Transferrin U31866 丨 2.71 
Squalene epoxidase (SQLE) D78130 2.55 
Collagen alpha 1 type 丨（Collal) Z78279 ‘ 2.52 
Cullin 2 (Cul2) NM_Q29402 | 2.11 
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Table 10 List of down-regulated ESTs 
Accession No. No. of Clones Differential Ratio 
AC093826 ~ 2 2 3 7 
AC091536 2 2 . 3 6 
AK020640 2 2 . 2 4 
AF130358 2 2 . 2 1 
AC091514 1 5 . 1 5 
AL603913 丨 2.61 
AFO18071 1 2 . 6 0 
AJ337659 1 2.58 
XM_034823 1 2.51 
AJ336756 1 2.48 
U31866 1 2 . 4 6 
AKO17872 1 2 .42 
ACO10907 1 2 . 3 6 
XM_017099 1 2.35 
XM_038566 1 2 . 3 4 
NM_026242 1 2.31 
AF220294 1 2.30 
AC092134 1 2.30 
AC087722 丨 2.：29 
XM一087143 丨 2.28 
J01436 1 2 . 2 6 
AC087067 1 2 . 2 2 
AC087534 1 2 . 1 8 
AC091000 1 2.16 
AF054018 1 2.15 
AC022538 丨 2 .14 
AC005177 1 2.11 
ACO 10530 1 2 .02 
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3.5 Reverse Transcription Polymerase Chain Reaction 
In order to confirm the microarray results, RT-PCR was performed. Both 3 
up-regulated and down-regulated genes were chosen from the gene lists. The criteria 
for the selection was based on the redundancy of the candidate genes, differential 
folds determined by microarray analysis and literature supports. Voltage-dependent 
anion channel 1 (Vdacl), Protein tyrosine phosphatase 4a 1 (PTPase 4a 1) and 
Choline transporter-like protein 1 splice variant a (CTLla) were chosen from up-
regulated genes. On the other hand, Ryanodine receptor type II (RyR2), G protein 
beta 1 subunit (rGbl) and Solute carrier family 3 member 1 (Slc3al) were chosen 
from down-regulated genes. 
G3PDH and p-actin genes were used to normalize the amount of cDNA of 
SHR and WKY samples. The normalized cDNA templates were used to perform 
RT-PCR with candidate genes. The PCR products were monitored at 25, 30 and 35 
cycles. The expression level of VDACl, PTPase4al and CTLla were higher in SHR 
ventricle (Figure 15) while that of RyR2, rGBl and Slc3al were lower (Figure 16). 
Thus, VDACl, PTPase and CTLla were shown to be up-regulated in hypertensive 
hearts while RyR2, rGBl and Slc3al were down-regulated. These results were 
matched with the microarray results. 
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Figure 15 Agarose gel electrophoresis of RT-PCR for up-regulated genes. 
Panel A: RT-PCR results of VDAC-1. Panel B: RT-PCR results of PTPase 4al. 
Panel C: RT-PCR results of CTLla. Panel D: RT-PCR results of G3PDH. Panel E: 
RT-PCR results of p-actin. Lanes 1，3，5: Expression of a particular gene from SHR 
ventricle cDNA at 25, 30 and 35 cycles. Lanes 2, 4，6: Expression of a particular 
gene from WKY ventricle cDNA at 25, 30 and 35 cycles. The relative intensity bar 
charts were shown. Purple color represents SHR sample and yellow color represents 
WKY. 
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Figure 16 Agarose gel electrophoresis of RT-PCR for down-regulated genes. 
Panel A: RT-PCR results of RyR2. Panel B: RT-PCR results of Gnbl. Panel C: RT-
PCR results of Slc3al. Panel D: RT-PCR results of G3PDH. Panel E: RT-PCR 
results of P-actin. Lanes 1，3, 5: Expression of a particular gene from SHR ventricle 
cDNA at 25，30 and 35 cycles. Lanes 2，4，6: Expression of a particular gene from 
WKY ventricle cDNA at 25, 30 and 35 cycles. The relative intensity bar charts were 
shown. Purple color represents SHR sample and yellow color represents WKY. 
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3.6 Northern Blot Hybridization 
Meanwhile, Northern blot hybridization was also performed to double-check 
the microarray results. Total RNAs of SHR and WKY samples were normalized by 
28S and 18S RNAs. The normalized amounts of RNA were loaded on a 
formaldehyde gel and the corresponding bands of 28S were shown after RNAs were 
transferred onto the membrane. The Northern blot hybridization results were shown 
(Figure 17 and Figure 18) which were also consistent to microarray and RT-PCR 
results. The band intensity ratios between SHR and WKY of candidate genes were 
calculated using WKY sample as reference reading. 
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Figure 17 Northern blot hybridization of up-regulated genes. 
Panel A: Northern blot hybridization results of VDAC-1. Panel B: Northern blot 
hybridization results of PTPase 4al. Panel C: Northern blot hybridization results of 
CTLla. Panel D: Northern blot hybridization results of p-actin. The upper panels 
show expression of up-regulation genes in ventricles of SHR (Lane S) and WKY 
(Lane W). The lower panels are the corresponding membrane photographs of 28S 
ribonucleic acid visualized under UV after RNA-transfer. The band intensity ratios 
were shown below. 
Panel A Panel B 
S W S W 
j y ^ mmmk 
^ 1.8 I ^ ^ ^ ^ H H f - ^ 2.6 kb 
. f l H I ^ H H I p H B H h 
4.10 1.00 3.22 1.00 
1.02 1.00 0.96 1.00 
Panel C Panel D 
s w s w j^n • • • 
^ 3.4 kb ^ 1.1 kb 
2.32 1.00 1.06 1.00 
0.99 1.00 0.97 1.00 
- 9 1 -
Results 
Figure 18 Northern blot hybridization of down-regulated genes. 
Panel A: Northern blot hybridization results of RyR2. Panel B: Northern blot 
hybridization results of Gnbl. Panel C: Northern blot hybridization results of SlcSal. 
Panel D: Northern blot hybridization results of P-actin. The upper panels show 
expression of up-regulation genes in ventricles of SHR (Lane S) and WKY (Lane W). 
The lower panels are the corresponding membrane photographs of 28S ribonucleic 
acid visualized under UV after RNA-transfer. 
Panel A Panel B 
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Chapter 4: Discussion 
4.1 Subtraction Quality 
Suppression Subtractive Hybridization is an efficient technique that enriches 
the differentially expressed transcripts in two RNA populations. SSH was employed 
to construct subtracted libraries for identification of candidate genes in hypertension-
induced responses. Since the clones of subtracted libraries are the starting materials 
for cDNA microarray fabrication, subtraction quality is a very improtant factor that 
affects the efficiency as well as the reliability of the following studies. Therefore, the 
subtraction efficiency analysis using a housekeeping gene is an essential test to verify 
that the equally expressed transcripts are successfully suppressed before the 
construction of subtracted libraries. From the experimental results, the common 
transcripts was reduced both in SHR- and WKY-subtracted libraries during the 
hybridization and PCR amplification steps in SSH. 
Although the common transcripts were effectively reduced by SSH, they 
were not completely eliminated from the subtracted libraries. As reported by other 
studies, the percentage of subtracted clones showing a differential expression by 
following confirmation were greatly varying from 25% to 69% (Chan J et al, 1997; 
von Stein OD et al’ 1997; Kuang WW et al, 1998; Terskikn A et al, 2000). Thus, a 
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verification step is necessary for further confirmation. Although Northern blot 
hybridization is the most direct and reliable approach to verify the differential 
expression of subtracted clones, it is inefficient and tedious for high throughput 
screening of genes. Therefore, microarray was applied to narrow down the potential 
targets for RT-PCR and Northern blot analysis. 
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4.2 Differential Screening by cDNA Microarray 
4.2.1 Elimination of False Subtracted Clones 
cDNA microarray is primarily a screening tool to eliminate the false positive 
subtracted clones from SSH. It is a high-throughput technique to monitor expression 
levels of hundreds to thousands of genes simultaneously. Candidate genes with 
consistent up-regulated and down-regulated expression patterns in repeated 
microarray hybridization would be chosen for further analysis. 
For cDNA microarray analysis, a total of 912 clones from two subtracted 
libraries were spotted on the microarray slides, in which 317 (35%) clones were 
shown differential expression in either one RNA population of SHR or WKY 
ventricle. This result matches with other studies using the combination method of 
SSH and microarray, the percentage of positive clones demonstrated by microarray 
in other studies ranged from 14% to 59% (Yang GP et al, 1999; Ahn JH et al, 2002; 
Gardmo C et ah 2002; RHO J et al, 2002). Based on the microarray results, those 
subtracted clones, either not quantifiable or the differential ratios below two, were 
rejected. The subtracted clones showing differential expression were subjected to 
sequencing. Thus, microarray screening eliminated most of the false positive 
subtracted clones and avoided unnecessary works on the common transcripts. 
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In addition, the differential ratios determined by microarray analysis as well 
as the number of redundant clones provided information for the selection of 
candidate genes. Thus, this combined approach would enhance the success rate in 
identifying the potential genes for further studies compared with random picking of 
subtracted clones from traditional SSH method. 
4.2.2 Limitations of cDNA Microarray 
cDNA microarray provides the mean to repeatedly measure the expression 
levels of a large number of genes in parallel. However, several limitations to 
microarray should be noted. A major limitation is a decreased sensitivity to the 
detection of genes with low expression level. Another disadvantage is that it is 
possible to confound microarray results through a process of cross-hybridization 
because of sequence similarity of the probes and the subtracted clones. This is 
actually more of a problem with spotted cDNA microarray since there is no attempt 
to spot onto the microarray only the portions of genes that are unique from others 
(Bunney WE et al, 2003). Although traditional methods that measure gene 
expression, e.g. Northern blot hybridization and RT-PCR, are relatively labor 
intensive, they provide high resolution and can be used to validate or extend 
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microarray data. Finally, tissue heterogeneity remains a persistent challenge for 
microarray. This is also true for Northern blot hybridization and serial analysis of 
gene expression (SAGE) and other non-in-situ methods. Microarray study of 
heterogeneous cell expression, e.g. ventricular tissue, may decrease the sensitivity by 
masking changes in gene expression. To overcome this problem, cardiomyocytes 
should be isolated and used as cell model for further function analysis of particular 
genes before any conclusion is drawn. 
- 9 7 -
Discussion 
4.3 Differentially Expressed Genes in Hypertensive Heart 
In order to further confirm the differentially expressed genes, both 3 up-
regulated and down-regulated genes were selected. RT-PCR and Northern blot 
hybridization analysis were then performed. Both RT-PCR and Northern blot 
hybridization analysis showed consistent results with microarray analysis on VDACl, 
PTPase4al, CTLla, RyR2, rGBl and Slc3al. In general, change in gene expression 
level is one of the major feedbacks to pathogenesis or abnormal stimulation in 
hypertensive hearts. Thus, VDACl, PTPase4al, CTLla, RyR2, rGBl and Slc3al are 
the potential genes for the studies of hypertensive-induced responses. 
Table 11 Summary of candidate genes. 
This table shows the up-regulated and down-regulated genes identified in the project 
with different techniques. 
Genes Accession No. No. of Clones Microarray RT-PCR Northern Blot 
Up-regu丨ation 
VDACl NM_031353 16 6.43 3.03 4.10 
PTPase4al NM_031579 13 4.97 3.00 3.22 
CTLla AJ420809 10 4.33 2.09 2.32 
Down-regulation 
RyR2 U95157 14 6.14 14.6 3.85 
rGBl U88324 13 4.44 3.95 3.23 
Slc3al NM_017216 11 5.69 1.89 4.17 
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4.3.1 Candidate Genes Showing Up-regulation 
4.3.1.1 Voltage-dependent Anion Channel 1 
Voltage-dependent Anion Channel (VDAC), also known as mitochondrial 
porin, is one of the VDAC isoforms. Mammalian VDACl is highly expressed in 
heart and kidney (Blachly-Dyson E and Forte M, 2001). It is a small, abundant pore-
forming protein found in the outer mitochondrial membranes of all eukaryotic cells. 
VDAC is believed to mediate trafficking of metabolites and ions across the outer 
mitochondrial membrane (Blachly-Dyson E et al，1994). VDAC pores are the major 
pathways for movement of adenine nucleotides through the outer membrane. It is the 
core component of permeability transition (PT) pore in the outer membrane while 
adenine nucleotide translocase (ANT) is located in the inner membrane. The pore 
complex also includes hexokinase, which binds to VDAC, and cyclophilin D 
(CyP-D), which binds to ANT (Baines CP et al, 2003). VDAC protein provides the 
binding site for hexokinase and glycerol kinase to the mitochondrial outer membrane. 
The binding of these kinases to mitochondrion is dynamic, tissue specific, varying 
during development, and depending on the metabolic state of the cell. The binding 
allows preferential access to mitochondrial ATP, thus regulating metabolism. In 
addition, malignant tumor cells have an increase in expression level, without 
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detectable structural difference, of VDACl and a higher hexokinase-binding 
capability compared to normal cells. VDACl may play a role in the abnormal growth 
process (Shinohara Y et al, 2000). 
Studies have shown that proapoptotic members of the Bcl-2 family such as 
Bax and Bak can bind directly to VDAC. Cytochrome c is released through VDAC 
and proteins of the Bcl-2 family regulate apoptosis by modulating VDAC activity in 
mammalian cells. VDAC is a positive regulator of mitochondrial calcium (Ca?.) 
accumulation and mitochondrial Ca^^ uptake plays a key role in the process of 
apoptosis. VDAC-overexpressing cells are more susceptible to apoptosis 
(Tsujimoto Y and Shimizu S, 2000; Shimizu S et al, 2001; Rapizzi E et al, 2002). 
Moreover, previous study of other research group has demonstrated an over-
expression of VDACl in human heart with hypertrophic cardiomyopathy (Lim DS et 
al, 2001). This matches with the experimental results showing an up-regulation of 
VDACl in hypertensive heart of SHR. Since VDACl is up-regulated both in hearts 
with hypertension and hypertrophic cardiomyopathy, it is a strong candidate gene in 
the study of pathological mechanism of hypertension-induced hypertrophy. 
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4.3.1.2 Protein Tyrosine Phosphatase 4a 1 
Protein tyrosine phosphatase 4a 1 (PTPase 4a 1 or PRL-1) plays diverse roles 
in cell signaling processes. Tyrosine phosphorylation is involved in the regulation of 
many cell functions, playing a critical role in the regulation of gene expression, 
enzymatic activity, cell cycle progression, cellular transport and motility. In the heart, 
protein kinases regulate contractility, ion transport, metabolism and gene expression. 
Dephosphorylation is equally important as phosphorylation and is mediated by 
protein phosphatases. Protein phosphatases are broadly classified into cell surface-
associated receptor and intracellular or nuclear non-receptor molecules (Sugden PH 
and Bogoyevitch MA, 1995). The non-receptor protein tyrosine phosphatase PRL-1 
is expressed at low level in the adults. It is an immediate-early growth response 
which is strongly up-regulated in regenerating liver and overexpression of PRL-1 
induces cellular transformation. These observations suggest roles for PRL-1 in cell 
growth and developmental process (Rundle CH and Kappeii C, 1999; Kong W et al, 
2000). In addition, overexpression of PRL-3, an isoform exhibiting about 76% 
identity to PRL-1, in the heart causes cardiac hypertrophy and a reduction of cardiac 
function (Matter WF et al, 2001). Thus PRL-1 is a potential candidate gene to be 
further studied. 
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4.3.1.3 Choline Transporter-like Protein 1 Splice Variant a 
Choline transporter-like protein 1 (CTLl) is a novel protein. It is so-called 
choline transporter-like protein because it shows choline transporter-like properties. 
The mRNA for CTLl is highly expressed in the rat spinal cord and brain, with 
prominent labeling of both oligodendrocytes and neurons. CTLl had initially been 
identified in the electric lobe of torpedo brain and its expression increase high-
affinity uptake of choline in a mutant yeast that are incapable of transporting or 
synthesizing choline, resulting in perturbations in phosphatidylcholine synthesis and 
membrane production. Only few studies of CTLl have been carried out, suggesting a 
role in lipid production (O'Regan S et al, 2000; Wille S et al, 2001; Meunier FM and 
0 'Regan S, 2002). However, expression level of CTLl and any roles in heart have 
not yet been reported. With CTLla, the splice variant of CTLl, even less is known 
about it. Therefore, it is difficult to draw a conclusion about the relationship between 
CTLla and pathogenesis of hypertrophy. 
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4.3.2 Candidate Genes Showing Down-regulation 
4.3.2.1 Ryanodine Receptor 2 
Ryanodine receptor (RyR) is a large conductance cation-selective ion channel 
that transverses the sarcoplasmic reticulum (SR) membrane. RyR is one of the largest 
known ion channel, which is a homotetramer comprised of four RyR subunits with a 
molecular weight of about 560, 000 Da (Marks AR, 2001; Reiken S et al, 2003). The 
mammalian isoforms of RyR have been identified as RyRl, RyR2 and RyR3. The 
primary structures of the 3 RyR isoforms have more than 65% amino acid homology. 
Ryanodine Receptor 2 (RyR2) is the predominant isoform in cardiac muscle (Marks 
AR, 2002). 
In cardiomyocyte, RyR2 is activated during excitation-contraction (E-C) 
coupling by Ca^.-induced Ca^ "" release (CICR). Cardiac E-C coupling is the process 
where by excitation of the cardiomyocyte, in the form of membrane depolarization, 
is used as a stimulus for the movement of Ca^ "" around cell to trigger contraction 
(Bers DM, 2002; Scoote M and Williams AJ, 2002). RyR2 functions as a CICR 
channel on intracellular Ca^ "" stores (sarcoplasmic reticulum) and mediates Ca^^ 
release triggered by Ca^ "" influx through the voltage-gated Ca^ "" channel. RyR2 is the 
major Ca^ "^ - release channel to maintain the normal range of luminal Ca^^ level in the 
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SR. In the cardiomyocytes with lower expression of RyR2, cytoplasmic Ca^^ derived 
from extracellular fluid during E-C coupling may be gradually accumulated in the 
SR, the excess cytoplasmic Ca^^ that cannot enter the overloaded SR may flow into 
the mitochondria, and finally cause defective organelles and dysfunction of the 
cardiomyocytes (Takeshima H et al, 1998). In addition, a decrease in mRNA level of 
RyR2 in rat hypertrophied heart has been reported (Rannou F et al, 1996; Szymanska 
G et al, 2000). Therefore RyR2 is also a strong candidate gene for further study 
about the pathological mechanism of hypertension-induced hypertrophy. 
4.3.2.2 Guanine Nucleotide-binding Protein pi Subunit 
Guanine nucleotide-binding protein pi subunit (Gnbl), also known as G-
protein pi subunit (rGBl), is one of the three subunits of G-protein. G protein are 
heterotrimers made up of each a, p and y subunits. The p subunit is tightly bound to 
the Y subunit and functions only as Py complex. The P subunit binds to a variety of 
effectors and is therefore directly involved in the modulation of effector activity. The 
p subunits are encoded by 5 genes and all five p subtype identified are all 
approximately 36kDa in size (Dowries GB and Gautam N, 1999). Expression of 
Gnbl has been shown in rat heart (Schnabel P and Bohm M, 1996). However, the 
-104 -
Discussion 
genes for the P subunits have not been as well characterized as the a subunits. 
Heterotrimeric G proteins are associated with signal transduction originating from 
the cell surface receptors. They are suggested to be involved in cardiac hypertrophy, 
cardiomyocyte apoptosis and heart failure (Hefti MA et al, 1997; Ruwhof C and van 
der Laarse A, 2000; Adams JW and Brown JH, 2001; Avkiran M and Haworth RS, 
2003). However, further investigation into the exact relationship between Gnbl and 
hypertension-induced hypertrophy should be carried out. 
4.3.2.3 Solute Carrier Family 3 Member 1 
Solute carrier family 3 member 1 (Slc3al or rbAT) is a heavy chain of a 
heterodimeric amino acid transporter that is also known as neutral and basic amino 
acid transport protein or L-type neutral amino acid transporter. Heterodimeric amino 
acid transporters are comprised of a heavy chain and a light chain. The human heavy 
chain Slc3al (rbAT) consists of 685 amino acids (about 85 kDa for glycosylated and 
78 kDa for unglycosylated) while rat Slc3al have 683 amino acids. Analysis of the 
amino acid sequences suggests that Slc3al has only one transmembrane helix with 
an intracellular NH2 terminus and an extracellular COOH terminus. However, studies 
with epitope-specific antibodies suggest that Slc3al may have four transmembrane 
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helices. The topology has not been rigorously probed. A part of Slc3al is suggested 
to be structurally related to glycosidases while glycosidase activity has not yet been 
demonstrated (Purroy J et al, 1996; Wagner CA et al, 2001). The type II membrane 
glycoprotein Slc3al is mainly expressed in kidney and small intestine (Tate SS et al, 
1992). It induces the transport activity for cystine as well as basic and neutral amino 
acids with the light chain. Slc3al has been shown to be closely related to type I 
cystinuria (Mizoguchi K et al, 2001). Besides kidney and intestine, Slc3al is also 
expressed in heart (Yan H et al, 1992). However, the functional roles of Slc3al in 
heart as well as the pathological consequence of its down-regulation have not been 
reported yet. 
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4.4 The Pros and Cons of Using Ventricular Tissue but not 
Cardiomyocytes 
In this study, the whole ventricle tissues, but not cardiomyocytes, of SHR and 
WKY rats were used for the construction of subtracted libraries, synthesis of cDNA 
probes in microarray and Northern blot hybridization, and synthesis of cDNA 
template for RT-PCR. However, in general, the normal myocardium is composed of 
a variety of cells. Cardiomyocytes, tethered within an extracellular matrix of fibrillar 
collagen, constitute about 25% in cell number; while non-cardiomyocytes, including 
endothelial and smooth muscle cells of the intramural coronary circulation and 
fibroblasts located in interstitial and perivascular spaces, account for the remaining 
(Weber KT, 2001). 
Although cardiomyocytes contribute only 25% in cell number, they represent 
over 80% of the heart mass. Ventricular hypertrophy is mainly based on the growth 
of cardiomyocyte, which may or may not be accompanied by other iterations in 
tissue structure. The use of ventricular tissue in SSH allows screening of 
differentially expressed genes in all cell types in the ventricle. In hypertensive heart 
disease, non-cardiomyocytes, e.g. fibroblasts, are proposed to account for a 
pathologic structural remodeling. 
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However, tissue heterogeneity may decrease the sensitivity in cDNA 
microarray by masking the changes in gene expression. Moreover, the differentially 
expressed genes should be verified whether the genes correspond to changes in 
expression of cardiomyocytes or non-cardiomyocytes. The shortcomings of the use 
of whole ventricle can be overcome by using purified cardiomyocytes for subsequent 
study on individual candidate genes. 
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4.5 Future Prospect 
Although several candidate genes have been identified by SSH and cDNA 
microarray techniques, it is still far from drawing a conclusion on the roles of 
candidate genes in the pathological mechanism of hypertension-induced hypertrophy. 
Before the conclusion is drawn, further studies should be performed to expose the 
pathological consequent of change in expression level of these candidate genes. 
4.5.1 Expression Profiling of Candidate Genes at Different Stages 
The development of hypertension-induced heart failure can be generally 
divided into several stages including normal, pre-hypertensive, developing, 
hypertensive, hypertrophy and heart failure. Expression level of a particular gene is 
varying at different stages. Therefore, gene expression profiling of SHR would be 
performed to provide details of candidate genes during the development of 
hypertensive heart disease. Since changes in expression of genes at different stages 
play different roles in pathogenesis, gene profile may give some hints to figure out 
hypertrophy-induced genes especially those expression levels change during the 
hypertensive stage to hypertrophy. 
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4.5.2 In vitro Studies of Candidate Genes 
The functional studies of candidate genes would be carried out by using in 
vitro models, Rattus norvegicus cardiac myoblast cell line H9C2 and primary 
cardiomyocyte culture. H9C2 cell will be induced to differentiate by low serum 
medium, which mimics the differentiated adult cardiac cells. On the other hand, 
cardiomyocyte from normal adult rat heart would be isolated. Cardiomyocytes can be 
purified up to 90% by pre-plating the collagenase-dissociated ventricular tissue on a 
cell-culture dish for dish for several times and harvesting the suspending cells. 
4.5.2.1 Over-expression of up-regulated genes in Normal Cardiac Cells 
Over-expression of up-regulated genes would be employed to evaluate the 
pathogenic potential of those candidate genes on hypertension-induced hypertrophy. 
The full-length cDNAs of up-regulated genes will be cloned into a mammalian 
expression vector, e.g. pcDNA4 vector (Invitrogen™ Life Technologies, Carlsbad, 
CA), and the recombinant constructs will be verified by sequencing. They will be 
transfected by lipofectamine™ reagent (Invitrogen™ Life Technologies, Carlsbad, 
CA) into differentiated H9C2 cells as well as adult cardiomyocytes. The cell number, 
size and morphology will be monitored. Since both DNA synthesis (Pasumarthi KB 
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et al, 2000) and apoptosis (Sabbah HN, 2000) are shown in hearts with myocardial 
hypertrophy. [^H]-Thymidine incorporation assay on DNA synthesis and DNA 
fragmentation essay on apoptosis will be also performed. 
4.5.2.2 Suppression of down-regulated genes in Normal Cardiac Cells 
Down-regulated genes in SHR will be disrupted in normal cardiac myocytes 
by introducing antisense (AS) oligodeoxynucleotides against the niRNA of these 
genes. Anti-sense studies can be performed by oligofectamine™ (Invitrogen^'^ Life 
Technologies, Carlsbad, CA). The cell number, size and morphology will be 
observed. The hypertrophic and apoptotic effects in normal cardiac cells by 
repression of these genes will be studied. 
4.5.3 In vivo Studies of Up-regulated Genes 
The suppression effects of up-regulated genes would be studied with animal 
models to examine the effect of those genes on hypertension-induced hypertrophy. 
Adult SHRs (22-24 week-old) will be treated with antisense (AS) or sense (S) 
oligodeoxynucleotides of particular up-regulated genes for 8 weeks. 
Oligodeoxynucleotides will be injected via the vein once a week. For control rat 
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models, 5% dextrose can be injected. Systolic blood pressure will be measured by 
tail-cuff method during the treatment. After eight weeks treatment, the rats will be 
dissected and the left ventricles weight/body weight of AS-treated, S-treated as well 
as 5% dextrose-treated rats will be measured (Kagiyama S et al’ 2003). To study the 
suppression effects of those genes on different stages, this experiment would be 
repeated with different stages of hypertensive rats. 
4.5.4 Confirmation of Other Potential Candidate Genes 
Besides those candidate genes confirmed by RT-PCT and Northern blot 
hybridization, a number of candidate genes were also showed either up-regulation or 
down-regulation in SHR ventricles by cDNA microarray technique. Further 
confirmation of these candidate genes would be performed. Meanwhile, a number of 
ESTs was shown to be differentially expressed in SHR. These ESTs encode for novel 
genes that have not been characterized yet. Thus, bioinformatics analysis would be 
applied in the prediction of the ORFs and the possible functional domains of these 
ESTs. 
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4.6 Conclusion 
In this research, differential gene expression pattern in the heart of 
spontaneously hypertensive rats at hypertensive stage were studied. The 
differentially expressed clones were successfully screened out by suppression 
subtractive hybridization and cDNA microarray analysis, in which 161 clones were 
shown to be up-regulated and 156 clones were shown to be down-regulated in the 
hypertensive SHR hearts. Voltage-dependent anion channel 1, protein tyrosine 
phosphatase 4al and choline transporter-like protein la were confirmed to be 
over-expressed in SHR ventricles by RT-PCR and Northern blot hybridization while 
ryanodine receptor 2，guanine nucleotide-binding protein (31 subunit and solute 
carrier family 3 member 1 were suppressed. The combination of suppression 
subtractive hybridization and cDNA microarray analysis is a powerful technique to 
figure out the hypertension-related genes for the study of pathological mechanism of 
hypertension-induced responses. 
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